Diniconazole_83657-24-3_DataSheet_MedChemExpress
厄贝沙坦说明书(英文)
Product InformationAVAPRO® (irbesartan)NAME OF THE MEDICINEAustralian Approved NameIrbesartan.Irbesartan is 2-butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro [4,4] non-1-en-4-one.Chemical StructureThe chemical structure of irbesartan isCAS number: 138402-11-6DESCRIPTIONIrbesartan is a white, to practically white, powder that is less than 0.1mg/mL soluble in water and slightly soluble in alcohol and methylene chloride.AVAPRO® (irbesartan) is a nonpeptide angiotensin II receptor (AT1 subtype) antagonist. It is available as 75, 150 or 300 mg film coated tablets for oral administration. The white, biconvex , oval-shaped tablets are marked with a heart on one side and on the other side 2871 (75mg) or 2872 (150mg) or 2873 (300mg). The inactive ingredients are: carnauba wax, croscarmellose sodium, hypromellose, lactose, macrogol 3000, magnesium stearate, microcrystalline cellulose, silicon dioxide, and titanium dioxide.PHARMACOLOGYPharmacodynamicsIrbesartan is a specific antagonist of angiotensin II receptors (AT1 subtype). Angiotensin II is an important component of the renin-angiotensin system and is involved in the pathophysiology of hypertension and in sodium homeostasis. Irbesartan does not require metabolic activation for its activity.Irbesartan blocks the potent vasoconstrictor and aldosterone-secreting effects of angiotensin II by selective antagonism of the angiotensin II (AT1 subtype) receptors localized on vascular smooth muscle cells and in the adrenal cortex. It has no agonist activity at the AT1 receptor and a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor (a receptor that has not been shown to be associated with cardiovascular homeostasis).Irbesartan does not inhibit enzymes involved in the renin-angiotensin system (i.e., renin, angiotensin converting enzyme [ACE]) or affect other hormone receptors or ion channels involved in the cardiovascular regulation of blood pressure and sodium homeostasis.In healthy subjects, single oral irbesartan doses of up to 300mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions. Inhibition was complete (≥90%) at the time of peak irbesartan concentrations and sustained for 24 hours (60% and 40% at300mg and 150mg, respectively).In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5-2 fold rise in angiotensin II plasma concentration and a 2-3 fold increase in plasma renin levels. Aldosterone plasma concentrations generally decline following irbesartan administration, however serum potassium levels are not significantly affected at recommended doses.In hypertensive patients, chronic oral doses of irbesartan (up to 300mg) had no effect on glomerular filtration rate, renal plasma/blood flow or filtration fraction. In multiple dose studies in hypertensive patients, there were no notable effects on fasting triglycerides, total cholesterol or HDL-cholesterol or fasting glucose concentrations. There was no effect on serum uric acid during chronic oral administration. Following repeated doses of irbesartan, there was no uricosuric effect.PharmacokineticsIrbesartan is an orally active agent and does not require biotransformation for its activity. AbsorptionFollowing oral administration, irbesartan is rapidly and well absorbed. In studies employing an injection and an oral solution containing radio-labelled irbesartan the average absolute oral bioavailability of irbesartan was 60- 80%. Median peak plasma concentrations generally occurred 1.5 -2 hours after oral administration of irbesartan capsules and tablets. Food did not affect the bioavailability.DistributionIrbesartan is 90% protein-bound in the plasma, and has negligible binding to cellular components of blood. The volume of distribution (V ss) is 53-93 Litres.MetabolismFollowing oral or intravenous administration of 14C irbesartan more than 80% of the circulating plasma radioactivity was attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (∼6%). Irbesartan undergoes oxidation primarily by thecytochrome P450 isoenzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. It is not metabolised by, nor does it substantially induce or inhibit most isoenzymes commonly associated with drug metabolism (i.e., CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, or CYP2E1). Irbesartan does not induce nor inhibit isoenzyme CYP3A4.ExcretionIrbesartan and its metabolites are excreted by both biliary and renal routes. About 20% of the administered radioactivity after an oral or intravenous dose of 14C irbesartan was recovered in urine with the remainder in the faeces. Less than 2% of the dose was excreted in urine as unchanged irbesartan.The terminal elimination half-life (t½) of irbesartan averaged 11 - 15 hours over a range ofirbesartan was 157 -176 mL/min, of which 3.0-3.5 mL/min was renal clearance. Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation (<20%) is observed in plasma upon repeated once-daily dosing.Special PopulationsIn male and female hypertensive subjects, higher (11-44%) plasma concentrations of irbesartan were observed in females than in males, although, following multiple dosing, males and females did not show differences in either accumulation or elimination half-life. No gender-specific differences in clinical effect have been observed.In elderly (male and female) normotensive subjects (65-80 years) with clinically normal renal and hepatic function, the plasma AUC and peak plasma concentrations (C max) of irbesartan are approximately 20%-50% greater than those observed in younger subjects (18-40 years). Regardless of age, the elimination half-life is comparable. No significant age-related differences in clinical effect have been observed.In black and white normotensive subjects, the plasma AUC and t½ of irbesartan are approximately 20-25% greater in blacks than in whites; the peak plasma concentrations (C max) of irbesartan are essentially equivalent.In patients with renal impairment (regardless of degree) and in haemodialysis patients, the pharmacokinetics of irbesartan are not significantly altered. Irbesartan is not removed by hemodialysis.In patients with hepatic insufficiency due to mild to moderate cirrhosis, the pharmacokinetics of irbesartan are not significantly altered.CLINICAL TRIALSThe antihypertensive effects of irbesartan were examined in seven (7) major placebo-controlled 8-12 week trials in patients with baseline diastolic blood pressures of 95-110 mmHg.The seven (7) studies of irbesartan monotherapy included a total of 1915 patients randomised to irbesartan (1-900mg) and 611 patients randomised to placebo. Once daily doses of 150 to900mg provided statistically and clinically significant decreases in systolic and diastolic blood pressure with a plateau in effect at doses above 300mg.Systolic/diastolic mean decreases in blood pressure at trough (24 hours post-dosing), compared to placebo, following 6 to 12 weeks of treatment were in the range of 7.5-9.9/4.6-6.2 mmHg with a 150mg dose, and 7.9-12.6/5.2-7.9 mmHg with a 300mg dose.Once-daily dosing with 150mg gave trough and mean 24 hour responses corresponding to those observed in patients receiving twice-daily dosing at the same total daily dose. Peak (3-6 hour) effects were uniformly, but moderately, larger than trough effects, with the trough-to-peak ratio for systolic and diastolic response generally between 60-70%.Two of the seven placebo-controlled trials identified above and two additional studies examined the antihypertensive effects of irbesartan and hydrochlorothiazide in combination. Addition of a low dose of hydrochlorothiazide (12.5mg) to irbesartan (75 to 300mg) once daily resulted in further diastolic blood pressure reductions at trough (24 hours post-dosing) of 2.3-4.8 mmHg and an overall systolic/diastolic placebo-subtracted reduction of up to13.6/11.5 mmHg at a dose of 300mg irbesartan and 12.5mg hydrochlorothiazide. Once daily dosing with 150mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg.In patients not adequately controlled (SeDBP≥90 mmHg) on irbesartan (up to 300mg) alone, the addition of 12.5mg hydrochlorothiazide gave an added reduction of up to 6.1 mmHg in trough (24 hours) diastolic blood pressure.In patients not adequately controlled (SeDBP 93-120 mmHg) on 25mg hydrochlorothiazide alone, the addition of irbesartan (75-150mg) gave an added systolic/diastolic mean reduction of 11.1/7.2 mmHg.Analysis of age, gender and race subgroups of patients showed that men and women, and patients over and under 65 years of age, had generally similar responses.The effect of irbesartan is apparent after the first dose, substantially present within 1-2 weeks, and reaches a maximal effect within 4-6 weeks. In long-term studies the effect of irbesartan appeared to be maintained for more than one year. After withdrawal of irbesartan, blood pressure gradually returned towards baseline; no rebound was observed. There was essentially no change in average heart rate in irbesartan-treated patients in controlled trials. Hypertension and type II diabetic renal diseaseThe Irbesartan Diabetic Nephropathy Trial (IDNT) was a multicentre, randomised, controlled, double-blind, morbidity and mortality trial comparing AVAPRO, amlodipine and placebo. In 1715 hypertensive patients with type II diabetes (proteinuria ≥ 900mg/day and serum creatinine 110-265 µmol/L in men and 90-265 µmol/L in women) the long-term effects (mean 2.6 years) of AVAPRO on the progression of renal disease and all-cause mortality were examined. In addition, a secondary end-point, the effect of AVAPRO on the risk of fatal or non-fatal cardiovascular events was assessed. Patients were randomised to receive AVAPRO 75mg, amlodipine 2.5mg, or matching placebo once-daily. Patients were thentitrated to a maintenance dose of 300mg AVAPRO, 10mg amlodipine, or placebo as tolerated. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and calcium channel blockers) were added as needed to help achieve blood pressure goal (≤ 135/85 or 10 mmHg reduction in systolic blood pressure if higher than 160 mmHg) for patients in all groups. AVAPRO demonstrated a 20% relative risk reduction in the composite primary endpoint (first occurrence of any of the following: doubling of serum creatinine, end-stage renal disease or all-cause mortality) compared to placebo (95% CI (3%, 34%), p =0.023) and a 23% relative risk reduction compared to amlodipine (95% CI (7%, 37%), p = 0.006). When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed. Similar blood pressure was achieved in the AVAPRO and amlodipine groups. There was no significant difference in the assessment of fatal or non-fatal cardiovascular events (cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, permanent neurologic deficit attributed to stroke, or above-the-ankle amputation) among the three treatment groups.The study of the Effects of Irbesartan on MicroAlbuminuria in Hypertensive Patients with Type 2 Diabetes Mellitus (IRMA 2) was a multicentre, randomised, placebo-controlled, double-blind morbidity study, conducted in 590 hypertensive patients with type II diabetes, microalbuminuria (20 - 200mcg/min; 30 - 300mg/day) and normal renal function (serum creatinine ≤ 130 µmol/L in males and ≤ 100 µmol/L in females). The study examined as a primary endpoint the long-term effects (2 years) of AVAPRO on the progression to (overt) proteinuria (urinary albumin excretion rate [AER] > 200µg/min [> approximately300mg/day] and an increase in AER of at least 30% from baseline). In addition, after one and two years of treatment, the effect of AVAPRO on the change in overnight AER and the change in 24-hour creatinine clearance was assessed. Patients were randomised to receive AVAPRO 150mg, AVAPRO 300mg, or matching placebo once daily. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve blood pressure goal (≤ 135/85 mmHg) for patients in all groups. AVAPRO 300mg demonstrated a 70% relative risk reduction in the development of clinical (overt) proteinuria compared to placebo (95% CI (39%, 86%), p = 0.0004). AVAPRO 150mg demonstrated a 39% relative risk reduction in the development of proteinuria compared to placebo (95% CI (-8%, 66%), p = 0.085). In the intent to treat analysis, when the primary endpoint is adjusted for urinary albumin excretion rate and mean arterial pressure, AVAPRO 300mg demonstrated a 68% relative risk reduction, (95% CI (35%, 85%), p=0.002). The slowing of progression to clinical (overt) proteinuria was evident as early as three months and continued over the 2 year period. The decline in 24-hour creatinine clearance did not differ significantly among the 3 groups. Regression to normoalbuminuria (< 20µg/min; <30mg/day) was more frequent in the AVAPRO 300mg group (34%) than in the placebo group (21%).The adverse experiences reported in these two studies are summarised under ADVERSE REACTIONS- Hypertension and Type II Diabetic Renal Disease and PRECAUTIONS - Effect on Laboratory Tests.INDICATIONSAVAPRO is indicated for the treatment of hypertension.AVAPRO is indicated for delaying the progression of renal disease in hypertensive type II diabetics with persistent micro-albuminuria (≥ 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.CONTRAINDICATIONSAVAPRO is contraindicated in patients who are hypersensitive to irbesartan or to any other component of the AVAPRO formulation.Pregnancy (See PRECAUTIONS-Use in Pregnancy)PRECAUTIONSHypotension - Volume-Depleted PatientsIrbesartan has been rarely associated with hypotension in hypertensive patients without other co-morbid conditions. Symptomatic hypotension, as with ACE inhibitors, may be expected to occur in sodium/volume-depleted patients such as those treated vigorously with diuretics and/or salt restriction, or on haemodialysis. Volume and/or sodium- depletion should be corrected before initiating therapy with irbesartan or a lower starting dose (e.g. 75 mg) should be considered. Patients undergoing haemodialysis should receive a starting dose of 75 mg and the dose should be adjusted according to B.P. response.Renal FunctionAs a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (e.g., hypertensive patients with renal artery stenosis in one or both kidneys, or patients with severe congestive heart failure), treatment with drugs that affect this system has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. The possibility of a similar effect occurring with the use of an angiotensin II receptor antagonist, including irbesartan cannot be excluded.In hypertensive type II diabetic patients with proteinuria (≥ 900mg/day), a population which has a high risk of renal artery stenosis, no patient treated with AVAPRO in IDNT had an early acute rise in serum creatinine attributable to renal artery disease. (See CLINICAL TRIALS)Experience is limited with irbesartan in patients with moderate to severe renal impairment; careful monitoring of renal function and potassium in such patients is advised. HyperkalaemiaWhile hyperkalaemia in uncomplicated patients with hypertension has not been reported with irbesartan, hyperkalaemia may occur during treatment with other drugs that affect the renin-angiotensin-aldosterone system, especially in the presence of renal impairment and/or heart failure. Adequate monitoring of serum potassium in patients at risk is recommended.Cardiac DisordersThe safety of irbesartan in the presence of heart failure has not been fully defined. Sudden death has occurred in some studies of patients with heart failure, and although such deaths may have reflected the natural history of the underlying heart failure, caution is recommended when treating such patients with irbesartan.At this time, experience is limited with irbesartan in the treatment of patients with ventricular dysfunction or cardiac arrhythmias; caution is advised.Effects on FertilityFertility and reproductive performance were not affected in studies of male and female rats at oral doses of up to 650 mg/kg/day (approximately 3 (male) and 8 (female) fold higher exposure, based on AUC, than that of humans at the maximum recommended clinical dose of 300mg/day).Use in Pregnancy Category DDrugs that act directly on the renin-angiotensin system can cause foetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature in patients who were taking angiotensin-converting enzyme inhibitors. When pregnancy is detected, AVAPRO should be discontinued as soon as possible.The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy have been associated with foetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased foetal renal function; oligohydramnios in this setting has been associated with foetal limb contractures, craniofacial deformation and hypoplastic lung development. Prematurity, intrauterine growth retardation and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. Mothers whose embryos and foetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of AVAPRO as soon as possible.Infants with histories of in utero exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria and hyperkalemia.When pregnant rats were treated with irbesartan from day 0 to day 20 of gestation, at doses of 50mg/kg/day and higher, transient effects (increased renal pelvic cavitation, hypoureter or subcutaneous oedema) were noted in full term rat foetuses but not in the young animals necropsied after 6 weeks of age. In pregnant rabbits, at doses of 30mg/kg/day, maternal mortality, abortion and early foetal resorptions were noted. No teratogenic effects were observed in the rat or rabbit.Use in LactationIrbesartan is excreted in the milk of lactating rats. It is not known whether irbesartan or its metabolites are excreted in human milk. A decision should be made whether to discontinue breast feeding or to discontinue the drug, taking into account the importance of irbesartan to the therapy of the mother and the potential risk to the infant.Paediatric UseSafety and effectiveness in paediatric patients have not been established.Use in the ElderlyAmong patients who received irbesartan in clinical studies, no overall differences in efficacy or safety were observed between older patients (65 years or older) and younger patients. GenotoxicityIrbesartan was not genotoxic in a series of assays for mutagenic and clastogenic effects. CarcinogenicityThe carcinogenic potential of irbesartan was assessed in two 104 week studies in mice and rats. No carcinogenic potential was observed in either species at doses of up to 500mg/kg/day (males rats) and 1000 mg/kg/day (mice and female rats) The AUC based exposure levels were 3 - 6 fold higher in mice, 3 fold higher in male rats and 25 fold higher in female rats than that of humans at the maximum recommended clinical dose of 300 mg/day.Effect on Laboratory TestsNo clinically significant changes in laboratory test parameters occurred in controlled clinical studies of hypertension. No special monitoring of laboratory parameters is necessary for patients with uncomplicated essential hypertension. Monitoring of potassium levels and renal function is recommended for patients with heart failure and those with moderate to severe renal impairment (see PRECAUTIONS).In two clinical studies of patients with hypertension and type II diabetic renal disease (IDNT and IRMA2) the following was reportedHyperkalaemia: In IDNT the percent of subjects with hyperkalaemia (>6 mmol/L) was 18.6% in the AVAPRO group compared to 6.0% in the placebo group. In IRMA 2 the percent of subjects with hyperkalaemia (>6 mmol/L) was 1.0% in the AVAPRO groups and none in the placebo group. In IDNT discontinuations due to hyperkalaemia in the AVAPRO group were 2.1% vs 0.36% in the placebo group. In IRMA 2 discontinuations due to hyperkalaemia in the AVAPRO groups were 0.5% vs none in the placebo group.INTERACTIONS WITH OTHER MEDICINESBased on in vitro data, no interactions would be expected to occur with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1 or CYP3A4. Irbesartan is primarily metabolised by CYP2C9, however, during clinical interaction studies, no significant pharmacodynamic interactions were observed when irbesartan was co-administered with warfarin (a drug metabolised by CYP2C9).Irbesartan does not affect the pharmacokinetics of digoxin. The pharmacokinetics of irbesartan is not affected by coadministration with nifedipine or hydrochlorothiazide.Potassium-sparing diuretics, potassium supplements, potassium containing salt substitutes. Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.LithiumReversible increases in lithium concentrations have been very rarely reported with irbesartan. Therefore if coadministration of AVAPRO and lithium proves necessary, careful monitoring of serum lithium levels is necessary.Combination use of ACE inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diureticsConcomitant use of a renin-angiotensin system inhibiting drug (ACE-inhibitor or angiotensin receptor antagonist), and an anti-inflammatory drug (NSAID, including COX-2 inhibitor) alone or with a thiazide diuretic may increase the risk of renal impairment, including possible acute renal failure. These effects are usually reversible. This includes use in fixed-combination products containing more than one class of drug. The combination of these agents should be administered with caution, especially in the elderly, volume-depleted, and in patients with pre-existing renal impairment. Renal function (serum creatinine) should be monitored after initiation of concomitant therapy, and periodically thereafter. The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.Effects on Ability to Drive or Use MachinesThe effect of irbesartan on ability to drive and use machines has not been studied. When driving vehicles or operating machines , it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.ADVERSE EFFECTSHypertensionIrbesartan has been evaluated for safety in approximately 5000 subjects in clinical studies, including 1300 hypertensive patients treated for over 6 months and over 400 patients treated for one year or more. Adverse events in patients receiving irbesartan were generally mild and transient with no relationship to dose. The incidence of adverse events was not related to age, gender, or race.In placebo-controlled clinical studies, including 1965 irbesartan-treated patients (usual duration of treatment 1 to 3 months), discontinuations due to any clinical or laboratory adverse event were 3.3 percent for irbesartan-treated patients and 4.5 percent for placebo-treated patients (p=0.029).Clinical adverse events, occurring in at least 1% of patients treated with irbesartan in placebo controlled trials are shown in the table below. The incidence of the same adverse events in the placebo control group is also shown.Clinical Adverse Events* in Placebo-Controlled Hypertension TrialsIncidencePercentage (%) of Patients*BODY SYSTEM/EVENT Irbesartann=1965Placebon=641GeneralFatigueInfluenza Chest pain 4.32.31.83.72.01.7CardiovascularOedemaTachycardia 1.51.22.30.9GastrointestinalDiarrhoeaNausea/VomitingDyspepsia/Heartburn Abdominal Pain 3.12.11.71.42.22.81.12.0Nervous SystemDizzinessHeadache aAnxiety/Nervousness 4.912.31.15.016.70.9DermatologicalRash 1.3 2.0 Musculoskeletal/ConnectiveMusc/Skel PainMusc/Skel Trauma a 6.61.96.60.5Renal/GenitourinaryUTI 1.1 1.4 RespiratoryUpper Resp. Infection Sinus AbnormalityCoughPharyngitisRhinitis 8.53.42.82.21.96.25.02.72.52.8a Statistically significant difference between irbesartan and placebo treatment groups.Adverse reactions that occurred in 2 or more hypertensive patients in clinical trials involving 3396 patients have been classified using standard terminology and in the following listing are categorised by body system and listed in order of decreasing frequency according to the following definitions: common adverse reactions are those occurring on one or more occasions in at least 1/100 but less than 1/10 patients; uncommon adverse reactions are those occurring in at least 1/1000 but less than 1/100 patients; rare adverse reactions are those occurring in less than 1/1000 patients.Cardiovascular : Uncommon: subjective rhythm disturbance, flushing, ECG abnormality, cardiac murmur, cardiac rhythm disturbance, orthostatic hypotension, atrial rhythm disturbance, bradycardia, hypotension; Rare:syncope, conduction disorder, myocardial infarction.Dermatologic : Uncommon: pruritus, facial erythema; Rare: dermatitis, acne,scalp-hair abnormality.Endocrine/Metabolic/Electrolyte Imbalance : Uncommon: sexual dysfunction, libido change; Rare: breast disorder, gout, hot flashes.Gastrointestinal :Uncommon: constipation, flatulence, dry mouth, abdomen distention; Rare: abnormal stool, decreased appetite, increased appetite, oral lesion, dysphagia, oesophagitis.General : Uncommon: weakness, hyperhidrosis, malaise, weight gain; Rare: cold sensation, warmth sensation, pain.Hematopoietic : Rare: anaemia.Immunology/Sensitivity Disorder : Uncommon: upper extremity oedema ; Rare: head/neck oedema.Musculoskeletal/Connective Tissue : Uncommon: muscle cramp, swelling extremity; Rare: arthritis, muscle ache, myalgia, extremity weakness, stiffness lower extremity.Nervous System : Uncommon: orthostatic dizziness, numbness, sleep disturbance, depression, emotion labile/disturbance, somnolence, vertigo, paresthesia; Rare: stress related disorder, tremor, coordination disturbance, disturbing dreams.Renal/Genitourinary : Uncommon: urination abnormality.Respiratory : Uncommon: epistaxis, dyspnea.Special Senses : Uncommon: vision disturbance, hearing abnormality; Rare: eye disturbance -other, eyelid abnormality, visual field abnormality, medication bad taste, taste disturbance. Hypertension and Type II Diabetic Renal DiseaseIn clinical studies (see CLINICAL TRIALS, Hypertension and type II diabetic renal disease), the adverse experiences were similar to those in clinical trials of hypertensive patients with the exception of orthostatic symptoms (dizziness, orthostatic dizziness and orthostatic hypotension) observed in IDNT (proteinuria ≥ 900mg/day, and serum creatinine from 90 - 265 µmol/L). In IDNT orthostatic symptoms occurred more frequently in the AVAPRO。
AZO FREE 纺织品禁用偶氮标准
禁用偶氮（AZO）染料的检测标准《生态纺织品标准100》中规定了有23种禁用芳香胺化合物，Eco-label（生态纺织品标签）中有22种禁用芳香胺化合物，ＧＢ／Ｔ18885—2002《生态纺织品技术要求》中规定了有23种禁用芳香胺化合物。
ＧＢ／Ｔ 18885—2002与Oeko-Tex stanDarD 100的禁用染料基本一致，而且限量都为20μｇ／ｇ。
而Eco-label 中比 Oeko-Tex stanDarD 100少了２，４－二甲基苯胺和４－氨基偶氮（AZO）苯，其限量为 30 μｇ／ｇ。
德国和欧盟的标准中对偶氮（AZO）染料的限量也为30μｇ／ｇ。
禁用偶氮（AZO）染料的检测标准如下：1、ＧＢ／Ｔ 17592.1—1998《纺织品禁用偶氮（AZO）染料检测方法气相色谱／质谱法》2、ＧＢ／Ｔ17592.2—1998《纺织品禁用偶氮（AZO）染料检测方法高效液相色谱法》3、ＧＢ／Ｔ17592.3—1998《纺织品禁用偶氮（AZO）染料检测方法薄层层析法》4、ＣＥＮＩＳＯ／ＴＳ 17234:2003 《皮革—化学测试—皮革中某些偶氮（AZO）染料的测定》5、ＥＮ 14362-1:2003《纺织品某些源自偶氮（AZO）染料的芳香胺的测定方法第1部分无需萃取的某些偶氮（AZO）染料测定》6、ＥＮ14362-2:2003《纺织品某些源自偶氮（AZO）染料的芳香胺测定方法第２部分萃取的偶氮（AZO）染料测定》7、德国标准§35ＬＭＢＧ82.02－2《日用品分析纺织日用品上使用某些偶氮（AZO）染料的检测》8、德国标准§35ＬＭＢＧ82.02－3《日用品测试皮革上禁用偶氮（AZO）染料的检测》9、德国标准§35ＬＭＢＧ82.02－4《日用品分析聚酯纤维上使用某些偶氮（AZO）染料的检测》10、德国标准ＤＩＮ53316:1997《皮革检验皮革某些偶氮（AZO）染料的测定》五、禁用偶氮（AZO）染料的检测原理禁用偶氮（AZO）染料的检测原理，是用不同的方法把织物上的染料萃取下来，进行还原分解，再对还原产物用气－质联用仪（ＧＣ／ＭＳＤ）或液相色谱仪来进行检测，检测其裂解后的产物。
RayBio
RayBio® Mouse PAI-I IQLEISA KitCatalog #: IQM-PAIIUser ManualLast revised April 6, 2023Caution:Extraordinarily useful information enclosedISO 13485 Certified3607 Parkway Lane, Suite 200Peachtree Corners, GA 30092 Tel: 1-888-494-8555 (Toll Free) or 770-729-2992, Fax: 770-206-2393Web: , Email: *******************RayBiotech, Inc.________________________________________RayBio® Mouse PAI-I IQLEISA Kit ProtocolTable of ContentsSection Page # I.Introduction3II.Reagents3III.Storage3IV.Additional Materials Required4V.Reagent Preparation4VI.Assay Procedure5VII.Assay Procedure Summary8VIII.Calculation of ResultsA. Typical DataB. Sensitivity and Recovery 8 9 9IX.Troubleshooting Guide10I. INTRODUCTIONThe RayBio®I mmuno Q uantitative E nzyme L inked I mumuno S orbent A ssay (IQELISA) is an innovative new assay that combines the specificity and ease of use of an ELISA with the sensitivity of real-time PCR. This results in an assay that is simultaneously familiar and cutting edge and enables the use of lower sample volumes while also providing more sensitivity. The RayBio® Mouse PAI-I IQLEISA Kit is a modified ELISA assay with high sensitivity qPCR readout for the quantitative measurement of Mouse PAI-I in serum, plasma, and cell culture supernatants. This assay employs an antibody specific for Mouse PAI-I coated on a 96-well PCR plate. Standards and samples are pipetted into the wells and PAI-I present in a sample is bound to the wells by the immobilized antibody. The wells are washed and a detection affinity molecule is added to the plates. After washing away unbound detection affinity molecule, primers and a PCR master mix are added to the wells and data is collected using qPCR. C t values obtained from the qPCR are then used to calculate the amount of antigen contained in each sample, where lower C t values indicate a higher concentration of antigen.II. REAGENTS1.PAI-I Microplate (Item A)**: 96 well PCR plate coated with anti-Mouse PAI-I.2.Wash Buffer I Concentrate (20x) (Item B): 25 ml of 20x concentrated solution.3.Standards (Item C): 2 vials of recombinant Mouse PAI-I.4.Assay Diluent B (Item E): 15 ml of 5x concentrated buffer.5.Detection Affinity Reagent for PAI-I (Item F): 2 vials of a 4x concentrated solution of anti-Mouse PAI-I affinity reagent.6.IQELISA Detection Reagent (Item G): 1 mL of a 10x concentrated stock.7.Primer Solution (Item I): 1.5 mL vial.8.PCR Master Mix (Item J): 1.4 mL vial.9.PCR Preparation buffer (Item K): 1mL vial of 10x concentrated buffer.10.Final Wash Buffer (Item L): 10 mL vial of 10x concentrated buffer.**The PCR plate used is a 0.2 mL, non-skirted 96-well plate (ThermoFisher, cat. no.:AB0600). Please ensure compatibility with your PCR machine prior to purchase. For additional information contact technical support (**************************).III. STORAGEMay be stored for up to 6 months at 2°to 8°C from the date of shipment. Standard (recombinant protein) should be stored at -20°C or -80°C (recommended at -80°C) after reconstitution. Opened PCR plate or reagents may be stored for up to 1 month at 2° to 8°C. Note: the kit can be used within one year if the whole kit is stored at -20°C. Avoid repeated freeze-thaw cycles.IV. ADDITIONAL MATERIALS REQUIRED1.Real-time PCR instrument, Bio-Rad recommended2.Precision pipettes to deliver 2 µl to 1 mL volumes.3.Adjustable 1-25 mL pipettes for reagent preparation.4.100 mL and 1 L graduated cylinders.5.Absorbent paper.6.Distilled or deionized water.7.Log-log graph paper or computer and software for data analysis.8.Tubes to prepare standard or sample dilutions.9.Heating block or water bath capable of 80°CV. REAGENT PREPARATION1.Bring wash buffer, samples, assay diluents, and PCR plate to room temperature (18 -25°C) before use. PCR master mix and Primer solution should be kept at 4°C at alltimes.2.Sample dilution: If your samples need to be diluted, 1x Assay Diluent B should be usedfor dilution of serum/plasma samples.Suggested dilution for normal serum/plasma: 2 -20 fold*.*Please note that levels of the target protein may vary between different specimens.Optimal dilution factors for each sample must be determined by the investigator.3.Assay Diluent B should be diluted 5-fold with deionized water.4.Briefly spin the Detection Antibody vial before use. Add 25 µL of 1x Assay Diluent B intothe vial to prepare a detection antibody concentrate. Pipette up and down to mix gently (the concentrate can be stored at 4°C for 5 days). This concentrate should be diluted 80-fold with 1x Assay Diluent B and used in step 4 of the Assay Procedure.5.PCR preparation buffer should be transferred to a 15 mL tube and diluted with 9 mL ofdeionized or distilled water before use.6.Final Wash Buffer should be transferred to a 15 mL tube and diluted with 9 mL ofdeionized or distilled water for every 1 mL of 10x concentrate used before use.7.Preparation of standard: Preparation of standard: Briefly spin a vial of Standards. Add400 µl 1X Assay Diluent B into Standards vial to prepare a 100 ng/ml standard solution.Dissolve the powder thoroughly by a gentle mix. Add 100 µl of the PAI-1 standard from the vial of Standards, into a tube with 400 µl 1X Assay Diluent B to prepare a 20,000pg/ml standard solution. Pipette 200 µl 1X Assay Diluent B into each tube. Use the 20,000 pg/ml standard solution to produce a dilution series (shown below). Mix eachtube thoroughly before the next transfer. 1X Assay Diluent B serves as the zero standard (0 pg/ml).400.00µL+ 100 µL100 µL + 200 µL 100 µL + 200 µL 100 µL + 200 µL 100 µL + 200 µL 100 µL+ 200 µL100 µL+ 200 µL20000pg/ml 6666.667pg/ml 2222.222pg/ml 740.741pg/ml 246.914pg/ml 82.305pg/ml 27.435pg/ml 0pg/ml8.If the Wash Buffer Concentrate (20x) contains visible crystals, warm to room temperature and mix gently until dissolved. Dilute 20 mL of Wash Buffer Concentrate into deionized or distilled water to yield 400 mL of 1x Wash Buffer.9.Prepare the IQELISA detection reagent by calculating how much will be needed. This may be accomplished by multiplying the number of wells to be assayed by the volume you plan to use per well. Once the volume of IQELISA detection reagent is known,prepare the reagent by diluting it 1:10 with deionized water and mixing thoroughly.VI. ASSAY PROCEDUREOptional Visual Aid: IQELISA [Good Laboratory Practice Guide]1.Bring all reagents and samples to room temperature (18 - 25°C) before use. It isrecommended that all standards and samples be run in triplicate. Partial plate runs may be accomplished by cutting the PCR plate into the desired number of strips using a pair of sturdy scissors, wire cutters, or shears. The remainder may be saved and used for a later date. If this is done, the PCR Plate Film should also be cut to a suitable size.2.Add 10-25 µL of each standard (see Reagent Preparation step 2) and sample intoappropriate wells. Volumes should be consistent between all wells, samples, andstandards. As little as 10 µL can be used if sample volume is limited, however thisincreases the chance of technical error. Ensure there are no bubbles present at thebottom of the wells. Dislodge any bubbles with gentle tapping or with a pipette tip being careful not to contact the sides or bottom of the well. Cover well and incubate for 1.5 -2.5 hours at room temperature.3.Discard the solution and wash 4 times with 1x Wash Solution. Wash by filling each wellwith Wash Buffer (100 µL) using a multi-channel Pipette or autowasher. Completeremoval of liquid at each step is essential to good performance. After the last wash,remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.4.Add 25 µL of prepared Detection Antibody (Reagent Preparation step 4) to each well.Incubate for 1 hour at room temperature with gentle shaking.5.Discard the solution. Repeat the wash as in step 3.6.Add 50 µL of prepared IQELISA detection reagent and incubate 1 hour with rocking(Reagent Preparation step 9)7.Discard the solution. Repeat the wash as in step 3, for a total of 6 washes.8.Add 75 µL of Final wash buffer to each well and incubate for 4 minutes with rocking.Remove the solution from each well and blot against paper towels.9.Add 75 µL of 1x PCR preparation buffer to each well and incubate for 10 seconds beforeremoving the buffer. Blot the plate after the buffer is removed to ensure completeremoval of the buffer.10.Add 10 µL of the Primer solution to each well of the plate. At this stage the plate can becovered and stored at -20°C for use the next day if needed.11.Add 10 µL of PCR Master Mix to each well and pipette thoroughly to mix the well (atleast 3x up and down).12.Cover the plate with the supplied PCR Plate Film, taking care to insure the film iscompletely and even pressed onto the plate, creating an air tight seal around each well of the plate.Optional Visual Aid: Sealing the plate [qPCR]13.Place the plate into a real-time PCR instrument using a FITC compatible wave length fordetection with the following settings for cycling1.2 minute activation at 95°C2.15 seconds 95°C denaturation3.25 seconds 60°C annealing/extension4.Repeat steps 2 and 3 34x**Optional: Include a melt curve to view potential plate contamination that can causehigh background and lower the sensitivity. This can be seen in the visual aid onYouTube.VII. ASSAY PROCEDURE SUMMARY1.Prepare all reagents, samples and standards as instructed.2.Add 25 µL standard or sample to each well. Incubate 1.5 - 2.5 hours at roomtemperature.3.Add 25 µL Detection Antibody to each well. Incubate 1 hour at room temperature.4.Add 50 µL of IQELISA Detection Reagent to each well. Incubate 1 hour5.Add 10 µL Primer solution and 10 µL of PCR master mix to each well6.Run real-time PCRVIII. CALCULATION OF RESULTSThe primary data output of the IQELISA kit is C t values. These values represent the number of cycles required for a sample to pass a fluorescence threshold. As the DNA is amplified additional fluorescent signal is produced, with each cycle resulting in an approximate doubling of the DNA. Therefore, higher levels of DNA (directly related to the amount of antigen in the sample) result in lower C t values.Calculate the mean C t for each set of triplicate standards, controls and samples. Subtract the C t value of each sample from the control to obtain the difference between the control and sample (Delta C t). Plot the values of the standards on a graph using a log scale for concentration on the x axis. This graph is the quickest way to visualize results, although not the most accurate. If this method is used the concentration of unknown samples can be estimated using a logarithmic line of best fit.The line of best fit will have an equation y = mln(x)+b, where y is the Delta C t value and x is the concentration. It may be helpful to use 5 significant figures for m and b to minimize rounding errors. To calculate the concentration of unknown sample this can be entered into Excel in the following format=EXP((y-b)/m))Where y is the Delta C t obtained during the assay, and b and m are obtained from the line of best fit.Alternatively, for a more accurate representation linear regression may be used. Both the Delta C t and Concentration can be transformed using a log base of 10, plotted on a graph as described above, along with a line of best fit (using a linear model). The equation of this line may be used to calculate the antigen concentration of unknown samples. This is the method used for the analysis spreadsheet for IQELISA available online.A. TYPICAL DATAThese data are for demonstration only. A standard curve must be run with each assay.B. SENSITIVITY and RECOVERYThe minimum quantifiable dose of PAI-I is typically 78.125 pg/ml, however levels as lower than 78.125 pg/ml may be detected outside of the quantification range.Serum spike tests show recovery is 75% with a range from 67% to 80%.Intraplate CV is below 10% for all samples and Interplate CV is below 15%.X. TROUBLESHOOTING GUIDEThis product is for research use only.©2023 RayBiotech, Inc11。
DINI ARGEO 产品说明书
DINI ARGEOSede / Head Office SERVICE ASSISTANCEItalySERVICE ASSISTANCEDini Argeo GmbH - GermanyWeighing whole with Dini Argeo indicator + Dini Argeo JBxxx Atex junction box + zener barriers +Dini Argeo Atex load receptor(s/n 123456)Description of the systemThe system is made up of the following parts:1. a Dini Argeo weight indicator;2. a kit of three ATEX certified zener barriers;3. an ATEX certified JBxxx junction box;4. a Dini Argeo Atex load receptor and relative accessories;5. one or more ATEX certified Dini Argeo load cells.This document is made in order to verify the connection of these parts, without considering further risks, in accordance with theEN 60079-25:2004 / IEC 60079-25:2003 norm.Composition1) A Dini Argeo weight indicator which belongs to one of these series: TRI, DFW, DGT, 3590, CPW, TRS, and which must be positioned in a safe zone.2) A PEPPERL+FUCHS Z996.H zener barrier for the excitation cable of the load cells; and two PEPPERL+FUCHS Z961.H zener barriers for the reference and the load cell signal cables; Dini Argeo MB4 code of the whole system of these three zener barriers. ATEX certificate: BAS01ATEX7005 - Issue 7Marking: II (1) GD [Ex ia] IIC (-20°C ≤ Ta ≤ +60°C)[Ex iaD]Ex data: Z966.H Z961.HUo= 24 V Uo= 17,4 VIo= 164 mA Io= 25 mAPo= 0,98 W Po= 0,05 WCo= 0,125 µF Co= 0,346 µFLo= 0,33 mH Lo= 14,8 mH3) Atex DINI ARGEO SRL JBxxx junction box.ATEX certificate: CEC 08 ATEX 019Marking:1131 II 2G Ex ib IIC T61131 II 2D Ex tD A21 IP65 T115°CEx data:Uo=Ui= 24V Io=Ii= 174mA Co=Ci=0mF Lo=Li=0mHor:Uo=Ui= 12V Io=Ii= 3,33A Co=Ci=0mF Lo=Li=0mH4) Dini Argeo Atex load received and relative accessories:- Electronic weighing platforms: T, RPLC, ET, EL, LP, PW, BP- Accessories: CSP, TSNC, TTNC, TQNC, TMNC, TLNC, ETATF, ETMTF, ETBTF, ETDTF, ETETF, ETFTF, ETHTF, ETLTF, ETAR, ETBR, ETDR, ETER, LPER, LPFR, ETPFI, ETPFIM20DINI ARGEOSede / Head Office SERVICE ASSISTANCEItalySERVICE ASSISTANCEDini Argeo GmbH - Germany- Carts: TB, TA- Raising frames: SGAQ, SGAX- Load cell assembly kit: KSPOT, KSPOC, KSB, KDSBN, KCPN, KRCK, KSTAETF01 technical file Dep.n° CEC-04/2036-ADF088Marking: II 2 GD c IIC T6 85 °C5) DINI ARGEO SRL Atex load cells which belongs to one of these series: SOT –SPSE - IBM3 - BM3 - SBX - STD - HM9B - IBM2 - BM2 - SPSC –CS – CSI – CF - CFI – STFC - SBCW –SBK -SBC –CFLI - CP –SPSB - IBM1 - BM1 –FXC -STG – IBM - BM - SBK-1KL - SBK-1K – SBK5000-1KL -CSG – CSGI - CCI – RCK - CBC – CBCI - DSBI - STFU – SPGS - SBH – SBCS - RSB - SBU – SPO – SPBC – SPH – SPG - CB17 - TH1042 - L6E - CZL6 - L6G - L6F - PW12C - SBZ.ATEX certificate: CEC 07 ATEX 093 X rev1Marking:- II 1G EExia IIC T6 (Ta -20÷+40°C) TX (Ta -20÷+65°C)- II 1D tD A20 TX°C (Ta -20÷+40°C) TX°C (Ta -20÷+65°C)Ex data:- U i= 24V, I i= 174mA, C i= trascurabile/negligible, L i= trascurabile/negligible- U i= 12V, I i= 3,33A, C i= trascurabile/negligible, L i= trascurabile/negligibleCable features between the zener barriers connection to the JBxxx Atex junction box:LY02506 manufacturer code (6x0,25mmq), Dini Argeo code LCCBConforms to the following norms: CEI 20-22 III cat. C; CEI 20-29, IEC 60228, CEI 20-11, CEI 20-35, IEC 60332.1, CEI 20-22 II, IEC 60332.C, CEI 20-37, IEC 60754, CEI 20-52R max a 20 °C = 75q/KmCc= 115 pF/mCs= 258,3 pF/mLc= 1,33 mH/KmCond./cond. test voltage= 2000 V x 5 minutesCond./shield test voltage= 2000 V x 1 minuteRated voltage= 300/500 VOperating temperature= -10/+70 °CThe verification of the Ex parameters of the whole has been executed, taking into consideration a maximum length of the cable between the zener barriers connection to the JBxxx Atex junction box of 50 m.DINI ARGEOSede / Head Office SERVICE ASSISTANCE Italy SERVICE ASSISTANCEDini Argeo GmbH - GermanyElectrical connectionCAREFUL • The barriers and the weight indicator must be installed outside of the hazardous area! • The safety requirements are respected only with a grounding of the zener barriers, Atex load cells, JBxxx Atex junction box,load cell shieldings, Atex load receptor, and of all the other parts of the whole Atex system (indicator holder column, etc.). • See the supplied instructions manual of all the parts which make up the whole atex system.ConclusionsThis whole of components does not produce and added risk.The whole Atex system resulting from this union can be used in a hazardous area, with the sole limitation of each single element and the Atex marking of the whole system (see Atex declaration of the whole system at the end of this document).DINI ARGEOSede / Head Office SERVICE ASSISTANCEItalySERVICE ASSISTANCEDini Argeo GmbH - Germany WARNINGS•The use of the whole in hazardous areas requires a particular attention and precautionary measures both during use and maintenance.•Do not install and use the various components in environments different than those provided for.•The installation, maintenance, and repair of the components must be executed by competent and authorised personnel.•The safety of the explosion-proof whole is guaranteed only if the system is installed, used, and taken care of following the instructions in this manual and in the relative manuals of the single components.•Avoid accumulations of electrostatic charges; therefore, in order to operate in a hazardous area, the operator or maintenance person must wear adequate work clothing.•Do not cover the single components with coverings made of materials which could be electro statically charged.•It is forbidden to modify or repair the Ex components with components which are non conforming to the relative certifications;this action could compromise the safety of these (with subsequent loss of the Ex approval) and the voiding of the product warranty.•It is forbidden to connect modules not listed in this document; this action could compromise the safety of the whole (with subsequent loss of the Ex approval). Contact Dini Argeo srl for further details.•Be very careful during the use: eventual sparks could cause an explosion.•Read the documents of all the devices which make up the whole system (zener barriers, junction boxes, load cells, etc.) and carefully follow the various instructions.INSTRUCTIONS FOR INSTALLING IN A HAZARDOUS AREAThis Atex whole must be installed and maintained, according to the applicable norms relative to the installations in a hazardous zone (different from the mines) classified for the presence of gas as ZONE 1, and/or the presence of dusts like ZONE 21, for example: EN 60079-14:2008 / IEC 60079-14:2007, EN 60079-17:2007 / IEC 60079-17:2007, EN 1127-1:2007 and all the norms applicable in the zone and in the installation environment.−Ground the zener barriers, the weight indicator, the Atex load cells, the Atex JBxx junction box, the cable shieldings, the Atex load receiver, and of all the other parts of the whole atex system (indicator holder column, etc.).WE DECLINE ALL RESPONSIBILITY FOR DAMAGES CAUSED BY THE UNOBSERVANCE OF THESEWARNINGSDINI ARGEOSede / Head Office SERVICE ASSISTANCEItalySERVICE ASSISTANCEDini Argeo GmbH - GermanyCE DECLARATION OF CONFORMITYWe DINI ARGEO Srl,Via della Fisica, 2041042 Spezzano di Fiorano - MODENA - ITALYWe declare under our responsibility that the whole described in this document conforms to the following directives:-ATEX 94/9/ECThe conformity is showing by observing the following norms:-EN 60079-0:2006-EN 60079-11:2007-EN 60079-25:2004 / IEC 60079-25:2003 -EN 61241-0:2007-EN 61241-1:2006 -EN 61241-11:2006 -EN 1127-1:2007 -EN 13463-1:2009 -EN 13463-5:2003Markings:-II 2GD IIC T6 T125°C (Ta -20÷+40°C) XSpezzano di Fiorano, Italy 12/01/2012SignatureMarco BertoniPresident。
NMB24-3 商品说明书
NMB24-3FootnotesBasic Non Fail-Safe actuator for controlling dampers in typical commercial HVAC applications.• Torque motor 90 in-lb [10 Nm]• Nominal voltage AC/DC 24 V • Control On/Off, Floating pointTechnical dataElectrical dataNominal voltageAC/DC 24 V Nominal voltage frequency 50/60 HzNominal voltage rangeAC 19.2...28.8 V / DC 21.6...28.8 V Power consumption in operation 2 W Power consumption in rest position 0.2 W Transformer sizing 4 VAOverload Protectionelectronic throughout 0...95° rotation Functional dataTorque motor90 in-lb [10 Nm]Direction of motion motor selectable with switch 0/1Manual override external push button Angle of rotation Max. 95°Angle of rotation note adjustable with mechanical stop Running Time (Motor)95 s / 90°Running time motor note constant, independent of load Noise level, motor 45 dB(A)Position indicationMechanical, 30...65 mm stroke Safety dataPower source ULClass 2 Supply Degree of protection IEC/EN IP54Degree of protection NEMA/UL NEMA 2Enclosure UL Enclosure Type 2Agency ListingcULus acc. to UL60730-1A/-2-14, CAN/CSA E60730-1:02CE acc. to 2014/30/EU and 2014/35/EU Quality Standard ISO 9001UL 2043 CompliantSuitable for use in air plenums per Section 300.22(C) of the NEC and Section 602 of the IMCAmbient humidity Max. 95% RH, non-condensing Ambient temperature -22...122°F [-30...50°C]Storage temperature -40...176°F [-40...80°C]Servicingmaintenance-free Weight Weight2.9 lb [0.94 kg]MaterialsHousing material UL94-5VA†Rated Impulse Voltage 800V, Type action 1, Control Pollution Degree 3.NMB24-3ApplicationOperationTypical specificationProduct featuresFor on/off and floating point control of dampers in HVAC systems. Actuator sizing should be done in accordance with the damper manufacturer’s specifications.The actuator is mounted directly to a damper shaft up to 1.05” in diameter by means of its universal clamp. A crank arm and several mounting brackets are available for applications where the actuator cannot be direct coupled to the damper shaft.The actuator is not provided with and does not require any limit switches, but is electronically protected against overload. The anti-rotation strap supplied with the actuator will prevent lateral movement.The NMB(X) series provides 95° of rotation and a visual indicator indicates position of theactuator. When reaching the damper or actuator end position, the actuator automatically stops. The gears can be manually disengaged with a button on the actuator cover.The NMB(X)24-3… actuators use a sensorless brushless DC motor, which is controlled by an Application Specific Integrated Circuit (ASIC). The ASIC monitors and controls the actuator’s rotation and provides a digital rotation sensing (DRS) function to prevent damage to the actuator in a stall condition. Power consumption is reduced in holding mode.Add-on auxiliary switches or feedback potentiometers are easily fastened directly onto the actuator body for signaling and switching functions.Floating point, on/off control damper actuators shall be electronic direct-coupled type, which require no crank arm and linkage and be capable of direct mounting to a shaft up to 1.05”diameter. Actuators shall have brushless DC motor technology and be protected from overload at all angles of rotation. Actuators shall have reversing switch and manual override on the cover. If required, actuators will be provided with a screw terminal strip for electricalconnections (NMX24-3-T). Run time shall be constant and independent of torque. Actuators shall be cULus listed, have a 5-year warranty, and be manufactured under ISO 9001 International Quality Control Standards. Actuators shall be as manufactured by Belimo.AccessoriesElectrical accessoriesDescriptionType Battery backup system, for non-spring return models NSV24 US Battery, 12 V, 1.2 Ah (two required)NSV-BAT Auxiliary switch 1 x SPDT add-on S1A Auxiliary switch 2 x SPDT add-onS2AFeedback potentiometer 140 Ω add-on, grey P140A GR Feedback potentiometer 1 kΩ add-on, grey P1000A GR Feedback potentiometer 10 kΩ add-on, grey P10000A GR Feedback potentiometer 2.8 kΩ add-on, grey P2800A GR Feedback potentiometer 500 Ω add-on, grey P500A GR Feedback potentiometer 5 kΩ add-on, greyP5000A GR Mechanical accessoriesDescriptionType Shaft clamp reversible, clamping range ø8...20 mm K-NA Mounting bracket for AF..ZG-100Mounting bracket ZG-101Mounting bracket ZG-103Mounting bracketZG-104Mounting kit for linkage operation for flat installationZG-NMA Shaft extension 240 mm ø20 mm for damper shaft ø8...22.7 mm AV8-25Shaft extension for 1/2" diameter shafts (3.8" L).ZG-NMSA-1Weather shield 13x8x6" [330x203x152 mm] (LxWxH)ZS-100Weather shield 406x213x102 mm [16x8-3/8x4"] (LxWxH)ZS-150Wrench 0.32 in and 0.39 in [8 mm and 10 mm]TOOL-06Linkage kitJackshaft Retrofit Linkage with Belimo Rotary ActuatorsZG-JSLElectrical installationActuators with appliance cables are numbered.Provide overload protection and disconnect as required.NMB24-3Actuators may also be powered by DC 24 V.Actuators Hot wire must be connected to the control board common. Only connect common toneg. (-) leg of control circuits. Terminal models (-T) have no-feedback.Actuators may be connected in parallel if not mechanically linked. Power consumption andinput impedance must be observed.Floating Point - Triac SourceWiring diagramsOn/Off Floating PointFloating Point - Triac Source Floating Point - Triac SinkNMB24-3 Dimensions。
Slide-A-Lyzer 渗透式洗脱袋说明书
Slide-A-Lyzer ™ Dialysis CassettesDoc. Part No. 2160729 Pub. No. MAN0011337 Rev.B.0WARNING! Read the Safety Data Sheets (SDSs) and follow the handling instructions. Wear appropriate protective eyewear,clothing, and gloves. Safety Data Sheets (SDSs) are available from /support .Product descriptionThe Slide-A-Lyzer ™Dialysis Cassettes are convenient devices for low molecular-weight contaminant removal, buffer exchange, desalting, and sample concentration. The cassette membrane is composed of low-binding regenerated cellulose and features a hermeticallysealed sample chamber to maintain the highest possible sample retention. These dialysis cassettes are manufactured using clean room conditions to ensure they are contaminant free. Samples are easily added and removed by penetrating the gasket with a hypodermic needle attached to a syringe. When the needle is removed, the gasket reseals, ensuring that no sample is lost from the cassette during dialysis.IMPORTANT! All Slide-A-Lyzer ™ Dialysis Cassettes that have the word "Hydrate" on the cassette pouch must be hydrated before use.Also hydrate all cassettes when using with low sample volumes (i.e., 100–200 µL in the 0.1–0.5 mL cassettes, 0.5–1 mL in the 0.5–3 mL cassettes, and 3–4 mL in the 3–12 mL cassettes) before use.Contents and storage[1]Cassettes in this size are best used for 0.2–0.5 mL sample volumes.[2]Kits include a package of cassettes, plus float buoys, syringes, and needles.[3]Gamma (γ) irradiated package of cassettes.Hydrate membranePerform the following steps for cassettes requiring hydration and for all cassettes used with low sample volumes:1.Remove the cassette from its pouch and slip into the groove of an appropriate size buoy.2.Immerse the cassette in dialysis buffer (Figure 1). Hydrate the3.5–20K cassettes for 1–2 minutes and the 2K cassettes for at least 2 minutes.3.Remove the cassette from buffer and remove excess liquidby tapping the edge of the cassette gently on paper towels. Do not blot the membrane.Add sampleNote: Do not allow the needle to contact the membrane.1.Fill the syringe with the sample, leaving a small amount of air in the syringe.2.With the bevel sideways, insert the tip of the needle through one of the syringe ports located at a top corner of the cassette.3.Inject the sample slowly. Withdraw air by pulling up on thesyringe piston (Figure 2).4.Remove the syringe needle from the cassette while retainingair in the syringe.Remove sampleNote: Use caution to avoid contacting the needle to the membrane.1.Fill the syringe with a volume of air equal to the sample size. For low-volume samples, fill the syringe with a volume of airapproximately equal to 2 times the sample volume.2.With the bevel sideways, insert the tip of the needle through another syringe port located at a corner of the cassette. Inject air slowlyinto the cassette to separate the membranes.3.Turn the unit so that needle is on the bottom and allow thesample to collect near the port. Withdraw the sample into thesyringe (Figure 3).Figure 1 Hydrate the membrane.Figure 2 Add sample.Figure 3 Remove sample.Detailed procedure for adding and removing samplesNote: Although quality assurance standards are stringent, there is always a slight chance of leakage. When dialyzing valuable samples, check the cassette for leaks by injecting and removing sterile ultrapure water immediately before adding the sample. Perform all cassette manipulations over a clean, dry work surface.Note: Use white Slide-A-Lyzer ™Cassette Float Buoys (Cat. No. 66430) for 0.5 and 3 mL cassettes. Use gray Slide-A-Lyzer ™Cassette Float Buoys (Cat. No. 66432) for 3–12 mL cassettes.1.Remove the cassette from its protective pouch by cutting along the dotted line.Note: To prevent contamination, handle the cassette by the plastic frame only. Do not touch the membrane with ungloved hands. The cassette can be placed into the groove of a buoy for use as a cassette stand.Note: For cassettes requiring hydration, see “Product description” on page 1 and Figure 1. Hydration increases membrane flexibilityand enables it to adjust more readily to the positive pressure created as the sample is added (Figure 2) and to the vacuum created when air is removed.2.Attach the hub of the hypodermic needle to the Luer-Lok ™Fitting of the syringe by firmlyscrewing it into place.CAUTION! Do not remove the plastic sheath from the needle until you are ready to fill the syringe with the sample. Usecaution to avoid injury from the hypodermic needle. Slide-A-Lyzer ™Dialysis Cassettes are designed for 18‑gauge, 1‑inch beveled needles (21‑gauge, 1‑inch beveled needles can also be used).3.Remove the protective sheath from the hypodermic needle and fill the syringe with the sample by immersing the needle in thesample and then slowly drawing back on the syringe piston.Note: When using small volumes, significant sample loss can occur in the syringe’s dead volume or from binding to the syringe surfaces. To minimize sample loss, fill the syringe with a small volume of air before sample uptake and use the air to void thesyringe’s dead volume. Syringes with low binding potential, such as airtight plastic syringes without rubber or silicon plungers, also can minimize sample loss.4.cassette slowly to avoid foaming.5.With the needle still in the cassette cavity, draw up onthe piston to remove air (Figure 5) and to compress the membrane windows so the sample contacts the greatest surface area. Use caution to prevent the needle fromcontacting the membrane. Minimal air left inside the cassette with low sample volumes should not significantly affect dialysis efficiency.6.Remove the syringe needle from the cassette while retainingthe air in the syringe. The gasket reseals and the membrane cavity has no (or minimal) air in direct contact with the sample.Figure 4 Add sample to the cassette.Figure 5 Remove air from the cassette.7.Slip the cassette into the groove of a buoy and float thisassembly in the dialysis solution of choice (Figure 6).Note: Use the dialysis buffer at 200–500 times the volume of the sample.8.Dialyze for the amount of time sufficient to remove lowmolecular weight compounds for the specific downstream application. A typical dialysis procedure is:a.Dialyze for 2 hours at room temperature or 4°C.b.Change the dialysis buffer and dialyze for another2 hours.c.Change the dialysis buffer and dialyze overnight at 4°C.9.To remove the sample, fill the syringe with a volume of air at least equal to the sample size. For low-volume samples, fill the syringewith a volume of air approximately equal to 2 times the sample volume.10.Penetrate the gasket with the needle through a top, unusedsyringe guide port. Discharge air into the cassette cavity to separate the membranes, which prevents needle penetration of the membrane (Figure 3 and Figure 7).Note: Avoid penetrating the guide ports more than one time to prevent gasket coring and subsequent sample loss.11.Turn the unit so that the needle is on the bottom and allowthe sample to collect near the port. Withdraw the sample into the syringe (Figure 8).Additional informationFor more information and protein dialysis, desalting, and concentration support, go to:/us/en/home/technical-resources/technical-reference-library/protein-purification-isolation-support-center/protein-dialysis-desalting-concentration-supportRelated products•Slide-A-Lyzer ™G3 Dialysis Cassettes(/us/en/home/life-science/protein-biology/protein-purification-isolation/protein-dialysis-desalting-concentration/dialysis-products/slide-a-lyzer-dialysis-cassettes )•Slide-A-Lyzer ™ Cassettes, Mini Devices, and Flasks(/us/en/home/life-science/protein-biology/protein-purification-isolation/protein-dialysis-desalting-concentration/dialysis-products )•Zeba ™Spin Desalting ColumnsFigure 6 Dialyze the sample.Figure 7 Add air to the cassette containing the sample.Figure 8 Remove sample from the cassette.(/us/en/home/life-science/protein-biology/protein-purification-isolation/protein-dialysis-desalting-concentration/zeba-desalting-products/zeba-spin-desalting-columns)•Pierce™ Protein Concentrators(/us/en/home/life-science/protein-biology/protein-purification-isolation/protein-dialysis-desalting-concentration/protein-concentrators)•Pierce™ Biotin and Dye Removal Spin Columns(/us/en/home/life-science/protein-biology/protein-purification-isolation/protein-dialysis-desalting-concentration/small-molecule-removal)•Protease and Phosphatase Inhibitor Cocktails and Tablets(/search/browse/category/us/en/90223020)•Pierce™ Microdialysis Plates(/us/en/home/life-science/protein-biology/protein-purification-isolation/protein-dialysis-desalting-concentration/dialysis-products/microdialysis)Limited product warrantyLife Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale at /us/en/home/global/terms-and-conditions.html. If you have any questions, please contact Life Technologies at /support.Thermo Fisher Scientific | 3747 N. Meridian Road | Rockford, Illinois 61101 USAFor descriptions of symbols on product labels or product documents, go to /symbols-definition.Revision history: Pub. No. MAN0011337The information in this guide is subject to change without notice.DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, THERMO FISHER SCIENTIFIC INC. AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.Important Licensing Information: These products may be covered by one or more Limited Use Label Licenses. By use of these products, you accept the terms and conditions of all applicable Limited Use Label Licenses.©2023 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified./support | /askaquestion。
迪雷尔（Drexel）乙醛三氯尿唑（Chlorpyrifos）15G农业昆虫毒（Agricultur
SAFETY DATA SHEETDREXEL CHLORPYRIFOS 15G AGRICULTURAL INSECTICIDEProduct Name: Drexel Chlorpyrifos 15G Agricultural InsecticideEPA Reg No.: 19713-505CAS NO: 2921-88-2Formula: C9H11ClNO3PSCompany: Drexel Chemical Company1700 Channel AvenueMemphis, TN 38106Synonyms: O,O-Diethyl O-3, 5, 6-trichloropyridin-2-yl phosphorothioateIdentifiers:EINECS: 220-864-4RTECS: TF6300000DOT information: See Section 14 for Transportation InformationEmergency Telephone Number:CHEMTREC Drexel Chemical Co.Tel: 1-800-424-9300 901-774-4370This product is an EPA FIFRA registered pesticide. Some of the classifications on this SDS are not the same as the FIFRA label. Certain sections of this SDS are superseded by federal law governed by EPA for a registered pesticide. Please see Section 15. REGULATORY INFORMATION for explanation.GHS classification:Health hazards: Acute toxicity – inhalation Category 2Skin corrosion/irritation Category 2Eye damage/ irritation Category 2BSpecific target organ toxicity –(single exposure) Category 1Specific target organ toxicity –(repeated exposure) Category 2Aquatic acute toxicity Category 1GHS label elements:Signal Word: DANGERHazard Statements: Toxic if swallowed.Fatal if inhaled.Causes skin irritation.Causes eye irritation.Causes damage to nervous system.May cause damage to nervous system through prolonged or repeated exposure.Very toxic to aquatic life.Precautionary Statements:Prevention: Prevention Wash thoroughly after handling.Do not breathe dust/fume/gas/mist/vapors/spray.Wear protective gloves/protective clothing. Examples of preferred glove barriermaterials include: Neoprene, Nitrile/butadiene rubber (“nitrile” or “NBR”) orPolyvinyl chloride (“PVC” or “vinyl”).Wear respiratory protection. Use a respirator with either an organic vapor-removing cartridge with a pre-filter approved for pesticides (MSHA/NIOSHapproval number prefix TC-23C) or a canister approved for pesticides(MSHA/NIOSH approval number prefix TC-14G).Do not eat, drink or smoke when using this product.Use only outdoors or in well-ventilated area.In case if inadequate ventilation wear respiratory protection.Avoid release to the environment from other than intended use.Response: If swallowed: Immediately call a poison control center/doctor. Rinse mouth. SeeSection 4: Note to Physician.If on skin: Wash with plenty of water. Call a poison center/doctor if you feelunwell. If skin irritation occurs; Get medical advice/attention. Take offcontaminated clothing and wash it before reuse.If inhaled: Remove person to fresh air and keep comfortable for breathing.Immediately call a poison center/doctor if person stops breathing.If in eyes: Rinse cautiously with water for several minutes. Remove contactlenses, if easy to do. Continue rinsing. If eye irritation persists: Get medicaladvice/attention.If exposed: Call poison center/doctor. Specific treatment see Note toPhysician, Section 4.Get medical attention if you feel unwell.Collect spillage.Storage: Store locked up. Store in well-ventilated place.Keep cool.Keep container tightly closed.Disposal: Disposal of contents/container must be in accordance with your local or arearegulations.Components CAS No.: % By Wt.: OSHA PEL: ACGIH TLV:Active Ingredient:Chlorpyrifos 2921-88-2 15.0% N/Av 0.2 mg/m3Inert Ingredients: N/A 85.0% N/A N/AHave the product container or label with you when calling a poison control center or doctor.Eye Contact: Hold eye open and rinse slowly and gently with water for 15 to 20 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eyes for at least 10 minutes. Obtain medical attention without delay, preferably from an ophthalmologist.If Swallowed: Call a poison control center or doctor immediately for treatment advice. Rinse out mouth then have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or doctor. Do not give anything by mouth to an unconscious person. Have product label with you when calling a poison control center or doctor.Skin Contact: Immediately flush skin with water while removing contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Destroy contaminated leather items such as shoes, belts, and watchbands.If Inhaled: Move person to fresh air. If person is not breathing, call 911 or an ambulance, then give artificial respiration, preferably mouth-to-mouth, if possible. Call a poison control center or doctor for further treatment advice.Note to Physician: This product contains an organophosphate that inhibits cholinesterase. Treat symptomatically. If exposed, plasma and red blood cell cholinesterase tests may indicate significance of exposure (baseline data are useful). Atropine, only by injection, is the preferable antidote. Oximes, such as 2-PAM/protopam, may be therapeutic if used early; however, use only in conjunction with atropine. In case of severe, acute poisoning, use antidote immediately after establishing an open airway and respiration. Contains petroleum distillate. Do not induce vomiting since vomiting may cause aspiration pneumonia.Fire Hazards: Thermal decomposition during a fire can produce fumes and irritating gases.Flammability classification (OSHA 29 CFR 1910.1200): N/AFlash point: NoneLower flammable limit (% by volume): N/AvUpper flammable limit (% by volume): N/AvFire Fighting Procedures: Keep people away. Isolate fire and deny unnecessary entry. Evacuate the area and fight the fire from upwind at a safe distance to avoid hazardous vapors or decomposition products. Dike and collect fire-extinguishing water to prevent environmental damage and excessive waste runoff.Firefighting media: Use foam, dry chemical, carbon dioxide, or water fog when fighting fires involving this product. Do not use water jet, as this may spread burning material. Minimize the use of water to avoid environmental contamination. Contain all runoff.Special Protective Equipment for Firefighters: Wear positive-pressure self-contained breathing apparatus (SCBA) and protective firefighting clothing (includes firefighting helmet, coat, trousers, boots, and gloves). Use full face shield and operate in positive pressure mode. Avoid contact with this material during firefighting operations. If contact is likely, change to full chemical resistant firefighting clothing with self-contained breathing apparatus. If this is not available, wear full chemical resistant clothing with self-contained breathing apparatus and fight fire from a remote location. For protective equipment in post-fire or non-fire clean-up situations, refer to the relevant sections.Hazardous Combustion Products: Hydrogen chloride, ethyl sulfide, diethyl sulfide, nitrogen oxides, carbon oxides, irritating fumes and smoke.NFPA: Health: Flammability: Reactivity:2 1 0(Rating: 4-Extreme, 3-High, 2-Moderate, 1-Slight, 0-Insignificant)Steps to be taken if Material is Released or Spilled:Sweep as much material as possible, keeping dust to a minimum and place in an approved chemical waste container. Wash the spill area with water containing a strong detergent, absorb with earth, sand or absorbent material and sweep up and place in approved chemical waste container. For large spills contact Drexel Chemical Co. See Section 13, Disposal Considerations, for additional information.Personal Precautions:Isolate area. Keep unnecessary and unprotected personnel from entering the area. Refer to Section 7, Handling for additional precautionary measures. Ventilate area of leak or spill. Use appropriate safety equipment. For additional information, refer to Section 8, Exposure Controls and Personal Protection.Environmental Precautions: Prevent from entering into soil, ditches, sewers, waterways and/or groundwater. See Section 12, Ecological Information.KEEP OUT OF REACH OF CHILDRENGeneral Handling: Avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Do not swallow. Avoid breathing dust. Use with adequate ventilation. Wear chemical protective equipment when handling. Keep away from heat, sparks and flame. See Section 8, Exposure Controls and Personal Protection.Storage: Store in a cool, dry, ventilated and secure area designated specifically for pesticides and away from heat sources. Keep in original containers and keep containers closed when not in use. Do not store in excessive heat. Do not store near children, food, foodstuffs, drugs or potable water supplies.Exposure Limits: TLV Chlorpyrifos 0.2 mg/m3Personal Protection:Eye/Face Protection: Wear safety glasses with side shields or chemical splash goggles to prevent dust from entering the eyes. If using a full face shield, always use safety glasses or goggles along with the face shield to ensure adequate protection of the eyes.Skin Protection: Wear long-sleeved shirt, long pants and shoes plus socks. Safety shower should be located in immediate work area. Remove contaminated clothing immediately after handling this product, wash skin area with soap and water, and launder clothing before reuse or dispose of properly. Items which cannot be decontaminated, such as shoes, belts and watchbands, should be removed and disposed of properly.Hand protection: Use gloves chemically resistant to this material. Examples of preferred glove barrier materials include: Neoprene, Nitrile/butadiene rubber (“nitrile” or “NBR”) or Polyvinyl chloride (“PVC” or “vinyl”).Respiratory Protection: Not normally required. Respiratory protection should be worn when there is a potential to exceed the exposure limit requirements or guidelines. When handling in enclosed areas, when large quantities of dusts are generated or prolonged exposure is possible in excess of the TLV, use a respirator with either an organic vapor-removing cartridge with a prefilter approved for pesticides (MSHA/NIOSH approval number prefix TC-23C) or a canister approved for pesticides (MSHA/NIOSH approval number prefix TC-14G).Ingestion: Avoid ingestion of even very small amounts; do not consume or store food or tobacco in the work area; wash hands and face before smoking or eating.Engineering Controls:Ventilation: When handling this product proper ventilation is required to maintain exposure below the TLV.Ventilate all transport vehicles prior to unloading. Facilities storing or utilizing this material should be equipped with and eyewash facility and safety shower.Physical State: GranuleColor: BrownOdor: MildFlash Point: NoneVapor Pressure (mmHg): N/ABoiling Point: N/AVapor Density (air = 1): N/ABulk Density (H2O = 1): 46.43 lbs./ft3Freezing Point: N/ASolubility in water: InsolublepH: N/AViscosity: N/A% Volatiles: >3%Stability/Instability: Avoid heating above 60°C (100°F). Chlorpyrifos undergoes exothermic decomposition at approximately 130°C (266°F), which can lead to higher temperatures and violent decomposition if generated heat is not removed.Conditions to Avoid: Keep this product away from excessive heat and moisture.Incompatible Materials: Avoid contact with strong alkalies, amines and oxidizers.Hazardous Polymerization: Will not occurThermal Decomposition: Decomposition products can include but are not limited to: Hydrogen chloride, ethyl sulfide and nitrogen oxides.Data presented for technical Chlorpyrifos:Acute ToxicityIngestion:∙Oral LD50, (rat): 223 mg/kgDermal:∙Dermal LD50, (rabbit): >5,000 mg/kgInhalation:∙LC50, (rat): > 0.2 mg/lEye Irritation (rabbit):∙Slight irritation resolved within 24 hoursSkin Irritation (rabbit):∙Mild irritation resolved within 7 daysSensitization Skin:∙Non-sensitizer (Guinea Pig)Carcinogenicity:∙Not likely to be carcinogenic in humansTeratogenicity, mutagenicity, and other reproductive effects: None knownData presented for the active ingredient Chlorpyrifos:ENVIRONMENTAL FATE:∙Very highly toxic to fish, highly toxic to daphnia, moderately to highly toxic to birds and serious hazard to Honeybees.Persistence and Degradability:∙Moderately persistent in soils degrading slowly through aerobic and anaerobic metabolism. Absorbs strongly to soil particles and is not readily soluble in water.Aquatic Toxicity:∙Rainbow Trout: 96 hour LC50: (0.007 – 0.051 mg/L)∙Bluegill Sunfish: 96 hour LC50: (0.002 – 0.010 mg/L)∙Daphnia magna: 48 hour EC50: (1.7 μg/L)Bees:∙LD50: (oral) 360 ng/bee; (contact) 70 ng/beeBird Toxicity:∙Mallard Duck: 8-day LC50: 180 ppm∙Bobwhite Quail: 8-day LC50: 423 ppmIf wastes and/or containers cannot be disposed of according to the product label directions, disposal of this material must be in accordance with your local or area regulatory authorities. This information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations. If the material as supplied becomes a waste, follow all applicable regional, national and local laws.DOT: UN-3077, Environmentally hazardous substances, solid, n.o.s., (Chlorpyrifos), 9, PG III, Marine Pollutant, RQ 1 lb.IMDG: UN-3077, Environmentally hazardous substances, solid, n.o.s., (Chlorpyrifos), 9, PG III, Marine Pollutant, RQ 1 lb.IATA: UN-3077, Environmentally hazardous substances, solid, n.o.s., (Chlorpyrifos), 9, PG III, Marine Pollutant, RQ 1 lb.Freight description: Agricultural Insecticide, solid, n.o.s.ERG Guide No.: 171This information is not intended to convey all specific regulatory or operational requirements/information relating to this product. Additional transportation system information can be obtained through an authorized sales or customer service representative. It is the responsibility of the transporting organization to follow all applicable laws, regulations and rules relating to the transportation of the material.OSHA Hazard Communication Standard:∙This product is a “Hazardous Chemical” as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.∙EPA FIFRA INFORMATION:This chemical is a pesticide product registered by the United States Environmental Protection Agency and is subject to certain labeling requirements under federal pesticide law. These requirements differ from the classification criteria and hazard information required for safety data sheets (SDS), and for workplace labels of non-pesticide chemical. The hazard information required on the pesticide label is listed out below.The pesticide label also includes other important information, including directions for use.∙EPA/CERCLA Reportable Quantity: Chlorpyrifos RQ = 1 lb.SARA/TITLE III:∙Section 302. Extremely Hazardous Substance Notification: This material is not known to contain any Extremely Hazardous Substances.∙Section 311/312. Hazard Categories:Fire HazardImmediate health hazardChronic health hazard∙Section 313. Toxic Chemical(s): This material is not known to contain any Toxic Chemical constituents.∙RCRA Waste Code: Not applicableCalifornia Proposition 65 (Safe Drinking Water and Toxic Enforcement Act of 1986):∙This product is not listed.Toxic Substances Control Act (TSCA):∙All components of this product are on the TSCA Inventory or are exempt from TSCA Inventory requirements under40 CFR 720.30Drexel Chemical Company recommends that each customer or recipient of this SDS to study it carefully and consult appropriate expertise, as necessary or appropriate, to become aware of and understand the data contained in this SDS and any hazards associated with the product. The information herein is provided in good faith and believed to be accurate as of the effective date shown below. However, no warranty, express or implied, is given. Regulatory requirements are subject to change and may differ between various locations. It is the buyer’s/user’s responsibility to ensure that his activities comply with all federal, state, provincial or local laws. The information presented here pertains only to the product as shipped. Since conditions for use of the product are not under the control of the manufacturer, it is the buyer’s/user’s duty to determine the conditions necessary for the safe use of this product. Due to the proliferation of sources for information such as manufacturer-specific SDSs, we are not and cannot be responsible for SDSs obtained from any source other than ourselves. If you have obtained an SDS from another source or if you are not sure that the SDS you have is current, please contact us for the most current version.Date Revised: June 22, 2016Supersedes: September 8, 2015。
TLC Pharmaceutical Standards 15(S)-Latanoprost Saf
SAFETY DATA SHEETPrint date December4,2019Section1.IdentificationsProduct name:15(S)-LatanoprostTLC ID:L-322Product Use:For laboratory use only.Not for use in humans or animals,drug,household or other use.Supplier/Manufacturer:TLC Pharmaceutical Standards Ltd.130Pony DriveNewmarket,ON,L3Y7B6,CanadaTelephone:(905)-898-3645Fax:(905)-898-0595Website:Section2.Hazards identificationsPhysical state:LiquidWarning:Harmful if swallowed,inhaled or in contact with skin.Routes of entry:Inhalation,skin,eyesGHS classification:Skin irritation(Category2)Serious eye damage/eye irritation(Category2)Acute toxicity,oral(Category4)Acute toxicity,dermal(Category4)Acute toxicity,inhalation(Category4)GHS Label elements,including precautionary statementsPictogram(s):Signal word:WarningHazards statements:H302+H312+H332Harmful if swallowed,in contact with skin or if inhaled.H315Causes skin irritation.H319Causes serious eye irritation.Precautionary statements:P261Avoid breathing dust/fume/gas/mist/vapours/spray.P271Use only outdoors or in a well-ventilated area.P280Wear protective gloves/protective clothing/eye protection/face protection.P302+P352IF ON SKIN:wash with plenty of soap and water.P305+P351+P338IF IN EYES:Rinse cautiously with water for several minutes.Removecontact lenses,if present and easy to do.Continue rinsing.position/Information on IngredientsCAS No.:145773-22-4Molecular Formula:C26H40O5Molecular Weight:432.60Synonyms:Isopropyl(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoateSection4.First-aid measuresGeneralConsult a physician.Show this safety data sheet to the doctor in attendance.Move out of dangerous area.If inhaledIf breathed in,move person into fresh air.If not breathing,give artificial respiration.Consult a physician.In case of eye contactRinse thoroughly with plenty of water for at least15minutes and consult a physician.In case of skin contactWash off with soap and plenty of water.Consult a physician.If swallowedDo NOT induce vomiting.Never give anything by mouth to an unconscious person.Rinse mouth with water.Consult a physician.Section5.Firefighting measuresConditions of flammabilityNot flammable or combustible.Suitable extinguishing mediaUse water spray,alcohol-resistant foam,dry chemical or carbon dioxide.Hazardous combustion productsHazardous decomposition products formed under fire conditions:carbon oxides,sodium oxides,nitrogen oxides Special firefighting proceduresWear self-contained breathing apparatus and protective clothing.Section6.Accidental release measuresPersonal precautionsWear respiratory protection.Avoid dust formation.Avoid breathing vapours,mist or gas.Ensure adequate ventilation.Evacuate personnel to safe areas.Avoid breathing dust.Environmental precautionsPrevent further leakage or spillage if safe to do so.Do not let product enter drains.Method and materials forcontainment and cleaning upMethod and materials for containment and cleaning upPick up and arrange disposal without creating dust.Sweep up and shovel.Keep in suitable,closed containers for disposal.Section7.Handling and storageHandlingAvoid contact with skin and eyes.Avoid formation of dust and aerosols.Provide appropriate exhaust ventilation at places where dust is formed.Keep away from sources of ignition.Take measures to prevent the buildup of electrostatic charge.StorageKeep refrigerated as specification of Certificate of Analysis.Keep container tightly closed in a dry and well-ventilated place.Section8.Exposure controls/personal protectionEngineering controlsUse mechanical exhaust or laboratory fumehood to avoid exposure.Personal protective equipmentRespiratory protectionWhere risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose combination(US)or type ABEK(EN14387)respirator cartridges as a backup to engineering controls.If the respirator is the sole means of protection,use a full-face supplied air e respirators and components tested and approved under appropriate government standards such as NIOSH(US)or CEN(EU)Hand ProtectionHandle with chemical-resistant gloves,solvent-resistant gloves.Gloves must be inspected prior to use.Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices.Wash and dry hands.Eye ProtectionFace shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH(US)or EN166(EU).Skin and body protectionComplete suit protecting against chemicals,flame retardant antistatic protective clothing.The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.Section9.Physical and chemical propertiesPhysical property:LiquidColour:ColorlessOdour:No data availableDensity:No data availableMelting Point/Freezing Point(°C):No data availableFlash Point(°C):No data availableExplosive Properties:No data availableOxidizing Properties:No data availableWater solubility:No data availableSolubility(other solvents):Methanol,AcetonitrileSection10.Stability and reactivityReactivity:No data available.Chemical stability:Stable under recommended storage conditions.Conditions to avoid:Heat,flames and sparks.Extremes of temperature and direct sunlight.Materials to avoid:oxidizing agents.Hazardous decomposition products:possible products formed under fire conditions:Carbon oxides.Section11.Toxicological informationAcute toxicityOral LD50:No data available.Inhalation.LC50:No data available.Dermal LD50:No data available.Skin Corrosion/Irritation:Toxic if absorbed through skin.May cause skin irritation.Eyes:May cause eye irritation.Acute and Chronic Health hazards:TLV:None verified.Effects of Overexposure:May causes eye,respiratory,and skin irritation.May be harmful by inhalation,ingestion,or skin absorption.To the best of our knowledge,the chemical,physical,and toxicological properties have not been thoroughly investigated Section12.Ecological informationNo data available.Section13.Disposal considerationsProductBurn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this material is highly flammable.Offer surplus and non-recyclable solutions to a licensed disposal company.Contact a licensed professional waste disposal service to dispose of this material.Contaminated packagingDispose of as unused product.Section14.Transport informationNon-hazardous for transport.IATA-Not regulatedSection15.Regulatory informationTLV:None verifiedSection16.Other informationThis product is not bioactive,not radioactive.It is for R&D use only.Not for drug,household or other uses.The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide.TLC Pharmaceutical Standards Ltd.extends no warranties with respect hereto and disclaims all liabilities from reliance thereon.All judgments as to the suitability of the data presented with respect to the use of this product are theresponsibility of the purchaser and intended user.。
Invitrogen TrueCut Cas9 Proteins 说明书
For Research Use Only. Not for use in diagnostic procedures.TrueCut ™ Cas9 ProteinsCatalog Nos.A36496, A36497, A36498, A36499, A50574, A50575, A50576, A50577WARNING! Read the Safety Data Sheets (SDSs) and follow the handling instructions. Wear appropriate protective eyewear, clothing, and gloves. Safety Data Sheets (SDSs) are available from thermofi/support .Product descriptionInvitrogen ™ TrueCut ™ Cas9 Proteins are used for genome editing applications with CRISPR technology. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR-Cas9 system. Incorporation of nuclear localization signals (NLS) aid its delivery to the nucleus, increasing the rate of genomic DNA cleavage. It is cleared rapidly, minimizing the chance for off-target cleavage when compared to plasmid systems (Liang et al ., 2015). The Cas9 nuclease hasbeen tested in a wide variety of suspension and adherent cell lines and has shown superior genomic cleavage efficiencies and cell survivability compared to plasmid-based CRISPR systems.Two types of TrueCut ™ Cas9 Proteins are available for selection, depending upon the requirements of your particular experiment:• TrueCut ™ Cas9 Protein v2 is a recombinant Streptococcus pyogenes Cas9 (wt) protein that is the preferred choice for most CRISPR genome editing procedures where the highest level of editing efficiency is required. • TrueCut ™ HiFi Cas9 Protein is an engineered high fidelity Cas9 protein which is ideal for experiments that are sensitive to off-target events, while still maintaining a high level of editing efficiency.Table 1.Contents and storagePub. No. MAN0017066Rev.D.0Storage and handling• Store TrueCut ™ Cas9 Protein v2 and TrueCut ™ HiFi Cas9 Protein at –20°C until required for use. • Maintain RNAse-free conditions by using RNAse-free reagents, tubes, and barrier pipette tips while setting up your experiments.Before you beginMaterials required but notprovided• TrueGuide™ Synthetic gRNAs (see /trueguide)orGeneArt™ Precision gRNA Synthesis Kit (Cat. No. A29377)• Lipofectamine™ CRISPRMAX™ Cas9 Transfection Kit (Cat. Nos. CMAX00001,CMAX00003, CMAX00008, CMAX00015, CMAX00030) (for most cell lines)orNeon™ Transfection System (Cat. Nos. MPK5000, MPK1025, MPK1096) (for highesttransfection efficiency in challenging cell types including suspension cell lines)• GeneArt™ Genomic Cleavage Detection Kit (Cat. No. A24372)• Opti-MEM™ I Reduced Serum Medium (Cat. No. 31985-062)• 1X TE buffer, pH 8.0 (Cat. No. AM9849) and nuclease-free water (Cat. No. AM9914G)Prepare working stock ofTrueGuide™ Synthetic gRNA If TrueGuide™ Synthetic gRNA is being used, resuspend the gRNA (sgRNA, crRNA, ortracrRNA) in1X TE buffer to prepare 100 μM (100 pmol/μL) stock solutions.Before opening, centrifuge each TrueGuide™ Synthetic gRNA tube at low speed (maximum1.RCF 4,000 × g) to collect the contents at the bottom of the tube, then remove the cap from thetube carefully.Using a pipette and sterile tips, add the required volume of 1X TE buffer to prepare 100 μM2.(100 pmol/μL) stock solutions.3.Vortex the tube to resuspend the oligos, briefly centrifuge to collect the contents at thebottom of the tube, then incubate at room temperature for 15–30 minutes to allow the gRNAoligos to dissolve.Vortex the tube again to ensure that all the contents of the tube are resuspended, then briefly4.centrifuge to collect the contents at the bottom of the tube.(Optional) Check the concentration of the resuspended oligos using the NanoDrop™5.Spectrophotometer (or equivalent) or a UV-base plate reader.6.(Optional) Aliquot the working stock into one or more tubes for storage.Use working stocks immediately or freeze at –20°C until needed for use.7.(Optional) Generate gRNA byin vitro transcription If using in vitro transcribed gRNA with TrueCut™ Cas9 Protein v2 or TrueCut™ HiFi Cas9Protein in CRISPR-Cas9-mediated genome editing, the GeneArt™ Precision gRNA SynthesisKit is recommended for preparation of the gRNA. For detailed instructions on how togenerate full length gRNA, see the GeneArt™ Precision gRNA Synthesis Kit User Guide (Pub.No. MAN0014538), at .Transfection guidelinesGeneral CRISPR/gRNAtransfection guidelines• The efficiency with which mammalian cells are transfected with gRNA varies accordingto cell type and the transfection reagent used. See Table 2 (page 3) for delivery reagentrecommendations.• For gene editing (including gene knockout) editing efficiency is highest with a 1:1 molarratio of gRNA to TrueCut™ Cas9 Protein v2 or TrueCut™ HiFi Cas9 Protein. In some celltypes such as iPSC and THP1, we have used up to 2 μg TrueCut™ Cas9 Protein v2 and400 ng gRNA per well in 24-well format.• For HDR knock-in editing, a 1.5:1 molar ratio of donor ssODN to gRNA or TrueCut™ Cas9Protein v2 or TrueCut™ HiFi Cas9 Protein is recommend for highest knock-in efficiency.The donor can be added directly to RNPs (a premixed gRNA-Cas9 protein). If using adsDNA donor, further optimization may be necessary to determine the appropriate donoramount, since the toxicity level is dependent on the length and format of the donor DNAand cell type.• The optimal cell density for transfection varies depending on cell size and growthcharacteristics. In general, use cells at 30–70% confluence on the day of transfectionwith lipid-mediated delivery, or 70–90% confluence for electroporation using the Neon™Transfection System.• After the optimal cell number and dosage of Cas9/gRNA and/or donor that providesmaximal gene editing efficiency is determined for a given cell type, do not varyconditions across experiments to ensure consistency.For an overview of the factors that influence transfection efficiency, see the “TransfectionBasics” chapter of the Gibco™ Cell Culture Basic Handbook, available at /cellculturebasics.• Use the TrueGuide™ Positive Controls (human AVVS1, CDK4, HPRT1, or mouse Rosa 26)and negative control gRNA (non-coding) to determine gRNA amount and transfectionconditions that give the optimal gene editing efficiency with highest cell viability. TheTrueGuide™ Positive and Negative sgRNA and crRNA Controls are available separatelyfrom Thermo Fisher Scientific. For more information, refer to /trueguide.• The cell number and other recommendations provided in the following proceduresare starting point guidelines based on the cell types we have tested. For multiplewells, prepare a master mix of components to minimize pipetting error, then dispense theappropriate volumes into each reaction well. When making a master mix for replicate wells,we recommend preparing extra volume to account for any pipetting variations.Recommended deliveryoptions• Choosing the right delivery reagent is critical for transfection and gene editing efficiency.See our recommendations in Table 2. For more information on transfection reagents, see/transfection.• For cell line specific transfection conditions using the Lipofectamine™ CRISPRMAX™Transfection Reagent or the Neon™ Transfection System, see the Appendix (page 13).• For best results, perform electroporation and transfection of cells using both TrueCut™Cas9 Proteins and TrueGuide™ Synthetic gRNA.HiFi Cas9 Protein.Table 2. Recommended delivery options for TrueCut™ Cas9 Protein v2 and TrueCut™Guidelines for verification of editing efficiencyVerification of gene editingefficiency• Before proceeding with downstream applications, verify the gene editing efficiency of thecontrol target and select the condition that shows the highest level of editing efficiency forfuture screening experiments.• To estimate the CRISPR-Cas9-mediated editing efficiency in a pooled cell population,use the GeneArt™ Genomic Cleavage Detection Kit (Cat. No. A24372), or performIon Torrent™ next generation sequencing or a Sanger sequencing-based analysis.• While the genomic cleavage detection (GCD) assay provides a rapid method forevaluating the efficiency of indel formation following an editing experiment, nextgeneration sequencing (NGS) of the amplicons from the edited population or Sangersequencing of amplicons cloned into plasmids give a more accurate estimate of thepercent editing efficiency and indel types for knockout and HDR knock-in editing.GeneArt™ Genomic CleavageDetection (GCD) Assay• After transfections, use the GeneArt™ Genomic Cleavage Detection Kit (Cat. No. A24372)to estimate the CRISPR-Cas9-mediated cleavage efficiency in a pooled cell population.• You can design and order target-specific primer sets for the GCD assay through ourTrueDesign Genome Editor, available at /crisprdesign.• To perform the GCD assay for the positive control, you need the primers listed in Table 3.We recommend using Invitrogen™ Custom DNA Value or Standard Oligos, available from/oligos, for target specific primer sets needed for the GCD assay.• You can set up the GCD assay in a 96-well plate format and analyze multiple gRNA-treated samples in parallel on a 2% E-Gel™ 48 agarose gel (48-well).• For more information and detailed protocols, see the GeneArt™ Genomic Cleavage DetectionKit User Guide (Pub. No. MAN0009849), available for download at /GCDManual.Table 3. Target sequences for the positive and negative control (non-targeting) TrueGuide™ Synthetic gRNA sequences.Guidelines for clone isolation and validationAfter you have determined the cleavage efficiency of the pooled cell population, isolate single cell clones for further validation and banking. You can isolate single cell clones from the selected pool using limiting dilution cloning (LDC) in 96-well plates or by single cell sorting using a flow cytometer.Limiting dilution cloning(LDC)• Based on the editing efficiency and estimated cell viability, you can estimate the number of single clones needed to obtain a desired knock-out (KO) clonal cell line. For example, if you desire a homozygous KO with mutations in both copies of a gene and the resulting GeneArt ™ cleavage detection efficiency was 50%, then the probability of having both alleles knocked out in any cell is 25% (0.5 × 0.5 = 0.25).If the probability of an indel leading to frame shift is 2/3, then the chance of having a homozygous KO is ~11% per cell [(0.5 × 0.5) × (0.66 × 0.66) = 0.11].• We recommend performing limiting dilution by targeting 0.8 cells/well, which requires you to resuspend the transfected cells (post-counting) at a density of8 cells/mL in complete growth medium, then transferring 100 µL of this to each well of a 96-well plate. If you plate at least ten 96-well plates in this manner and expect only 20% of cells tosurvive, then the probability of having homozygous KO clones in the 192 surviving cells will be 19–21 cells (192 × 11%).• Note that single cell clone survivability varies by cell type. Some cells that do not like to remain as single cells need to be plated at a low density to get well separated colonies, which will then have to be manually picked for further screening.Example LDC procedureusing 293FT cells1. Wash the transfected cells in each well of the 24-well plate with 500 µL of PBS. Carefully aspirate the PBS and discard.2. Add 500 µL of TrypLE ™ cell dissociation reagent to the cells and incubate for2–5 minutes at 37°C.3. Add 500 µL of complete growth medium to the cells to neutralize the dissociation reagent.Pipette the cells up and down several times to break up the cell aggregates. Make sure that the cells are well separated and are not clumped together. 4. Centrifuge the cells at 300 × g for 5 minutes to pellet.5. Aspirate the supernatant, resuspend the cells in an appropriate volume of pre-warmed(37°C) growth medium, then perform a cell count. 6. Dilute the cells to a density of 8 cells/mL of complete growth medium. Prepare a total ofSequence analysis• For next generation sequencing (NGS) based editing efficiency analysis, you canspecifically amplify the edited region and barcode amplicons by pooling all amplicons in a single tube and performing sequencing using various NGS platforms such as the Ion Torrent ™ Targeted Amplicon-seq Validation (TAV). For more information on NGS analysis, refer to Ion Torrent ™ targeted sequencing solutions at /ionapliseqsolutions .• For Sanger sequencing-based editing efficiency analysis, refer to our application note referenced at /sangercrispr .• Use the SeqScreener Gene Edit Confirmation App on Thermo Fisher ™ Connect todetermine the spectrum and frequency of targeted mutations (see Pub. No. MAN0019454 at . for details).50 mL of cell suspension at this cell density and transfer to a sterile reservoir.Note: You can also perform a serial dilution to get a better estimate of cell density.Using a multichannel pipettor, transfer 100 µL of the cell suspension into each well of 96-well7.tissue culture plates until the desired number of plates is seeded. Make sure to mix the cellsin between seeding the plates to avoid the formation of cell aggregates.Note: In general, we seed ten 96-well plates to achieve a large number of clones. Numberof plates to seed depends on the editing efficiency of pooled cell population and viability ofcells post single cell isolation.Incubate the plates in a 37°C, 5% CO2 incubator.8.Scan the plates for single cell colonies as soon as small aggregates of cells are visible under a9.4X microscope (usually after first week, depending on the growth rate of the cell line).Continue incubating the plates for an additional 2–3 weeks to expand the clonal populations10.for further analysis and characterization.Example single cell sortingprocedure in a 96-well plateusing flow cytometer Single cells can be sorted into a 96-well plate format using a flow cytometer with singlecell sorting capability. After sorting and expanding the single cell clones, analyze andcharacterize the clonal populations using suitable assays.1.Wash the transfected 293FT cells in each well of the 24-well plate with 500 µL of PBS.Carefully aspirate the PBS and discard.Add 500 µL of TrypLE™ cell dissociation reagent and incubate for 2–5 minutes at 37°C.2.Add 500 µL of complete growth medium to the cells to neutralize the dissociation reagent.3.Pipette the cells up and down several times to break up the cell aggregates. Make sure thatthe cells are well separated and are not clumped together.Centrifuge the cells at 300 × g for 5 minutes to pellet.4.5.Aspirate the supernatant, then wash the cell pellet once with 500 μL of PBS.Resuspend 1 × 106 cells in 1 mL of FACS buffer, then add propidium iodide (PI) to the cells at6.a final concentration of 1 µg/mL. Keep the resuspended cells on ice.Filter the cells using suitable filters before analyzing them on a flow cytometer with single7.cell sorting capability.Sort PI-negative cells into a 96-well plate containing 100 μL of complete growth medium. If8.desired, you can use 1X antibiotics with the complete growth medium.Incubate the plates in a 37°C, 5% CO2 incubator.9.Scan the plates for single cell colonies as soon as small aggregates of cells are visible under10.a 4X microscope. Colonies should be large enough to see as soon as 7–14 days (usually afterfirst week, depending on the growth rate of the cell line). You can perform image analysis toensure that the colonies are derived from single cells.11.After image analysis, continue incubating the plates for an additional 2–3 weeks to expandthe clonal populations for further analysis and characterization.Characterize edited clones You can analyze the single cell clones for purity and the desired genotype (homozygous orheterozygous allele) by various molecular biology methods such as genotyping PCR, qPCR,next generation sequencing, or western blotting.Supporting tools At Thermo Fisher Scientific, you can find a wide variety of tools to meet your gene editingand validation needs, including Invitrogen™ LentiArray CRISPR and Silencer™ Select RNAilibraries for screening, primers for targeted amplicon sequencing, antibody collection forknock-out validation, and ORF collections and GeneArt™ gene synthesis service for cDNAexpression clones that can be used for rescue experiment reagents.thermofisher .com/support | thermofisher .com/askaquestion thermofisher .comLimited product warrantyLife Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies’ General Terms and Conditions of Sale found on Life Technologies’ website at /us/en/home/global/terms-and-conditions.html . If you have any questions, please contact Life Technologies at www /support .Manufacturer: Thermo Fisher Scientific Baltics UAB | V. A. Graiciuno 8 | LT-02241 Vilnius, LithuaniaThe information in this guide is subject to change without notice.DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.Revision history:Pub. No. MAN0017066Important Licensing Information: These products may be covered by one or more Limited Use Label Licenses. By use of these products, you accept the terms and conditions of all applicable Limited Use Label Licenses.©2021 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified .。
异鼠李素
异鼠李素
编码品名规格单位
WR0861S异鼠李素20mg瓶
WR0861 异鼠李素100mg瓶中文名称：异鼠李素
中文别名：3,5,7-三羟基-2-(4-羟基-3-甲氧基苯基)苯并吡喃-4-酮英文名称：Isorhamnetin
别名：3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl) chromen-4-one
CAS号：480-19-3
分子式：C16H12O7
分子量：316.27
规格：20mg/瓶
纯度：HPLC≥98%
化学式
C16H12O7
分子量
316.2623
CAS登录号
480-19-3
EINECS登录号
207-545-5
熔点
307℃
沸点
599.4°C at 760 mmHg
密度
1.634g/cm3
外观
淡黄色针状结晶
闪点
227.8°C
流动相：………………………………甲醇-0.4%磷酸=50:50
检测波长：……………………………360 nm
色谱柱：………………………………ODS-BP
柱温：…………………………………室温
用途：对照标准品，用于分析对照，含量测定
异鼠李素的溶解性，异鼠李素在水中的溶解性，异鼠李素在生理盐水中的溶解性，异鼠李素在PBS缓冲液中的溶解性，异鼠李素在DMSO、乙醇等有机溶剂中的溶解性，异鼠李素在细胞实验方面的应用，异鼠李素在大鼠等动物实验方面的应用。
国内外法规禁用的偶氮染料检测标准
国内外法规禁用的偶氮染料检测标准2006年9月13日 9:48 来源：中国皮具网Oeko-Tex standard 100《生态纺织品标准100》中规定了有23种禁用芳香胺化合物，Eco-label(生态纺织品标签)中有22种禁用芳香胺化合物，GB/T18885—2002《生态纺织品技术要求》中规定了有23种禁用芳香胺化合物。
GB/T18885—2002与Oeko-Tex standard 100的禁用染料基本一致，而且限量都为20μg/g。
而Eco-label中比Oeko-Tex standard 100少了2，4-二甲基苯胺和4-氨基偶氮苯，其限量为30μg/g。
德国和欧盟的标准中对偶氮染料的限量也为30μg/g。
禁用偶氮染料的检测标准如下：(1)GB/Y 17592.1—1998《纺织品禁用偶氮染料检测方法气相色谱/质谱法》(2)GB/T 17592.2—1998《纺织品禁用偶氮染料检测方法高效液相色谱法》(3)GB/T 17592.3—1998《纺织品禁用偶氮染料检测方法薄层层析法》(4)CENISO/TS 17234:2003《皮革—化学测试—皮革中某些偶氮染料的测定》(5)EN 14362-1:2003《纺织品某些源自偶氮染料的芳香胺的测定方法第1部分无需萃取的某些偶氮染料测定》(6)EN 14362-2:2003《纺织品某些源自偶氮染料的芳香胺测定方法第2部分萃取的偶氮染料测定》(7)德国标准§35LMBG82.02-2《日用品分析纺织日用品上使用某些偶氮染料的检测》(8)德国标准§35LMBG82.02-3《日用品测试皮革上禁用偶氮染料的检测》(9)德国标准§35LMBG82.02-4《日用品分析聚酯纤维上使用某些偶氮染料的检测》(10)德国标准DIN53316:1997《皮革检验皮革某些偶氮染料的测定》皮革环保测试一般包含以下测试项目,具体可与我联系:A. PH ValuPH 值B. Formaldehyde content 甲醛含量C. Chromium Vi Content 六价铬D. Cleavable Arylamines (Banned Azo Dyes) 可裂解出致癌芳香胺的偶料)E. Cancerogenic Dyes 致癌染料F. Heavy metal content 重金属G. PCP（五氯苯酚）/TeCP （四氯苯酚）/OPP（邻苯基酚）H. ODS 破坏臭氧层的物质I. Free fatty acid 游离脂肪酸含量J. Organotin Compounds ( TBT, DBT, MBT, TPhT, TeBT, MOT, DOT, TcyT, TPT, TOT)K. APEO ( NPEOs, OPEOs, NP, OP) 烷基苯酚聚乙氧基醇L. Short Chain Chlorinated Paraffins (SCCP)短链氯化石蜡M. Soluable mineral tanning agents (sum.-Al,Cr,Ti,Zr) 可溶性矿物鞣剂(铝,铬,钛N. Perfluorooctane Sulfonates(PFOS) 全氟辛烷磺酰化合物O. Leather – Determination of Matter Soluble in dichloromethane 皮革二定P. Standard Test Method for Hexane Extraction of Leather皮革己Q. Six individual Phthalates 邻苯二不好意思还有一个问题请教大家，皮具出口德国，客户要求办理的AZO是什么东东啊？是一项测试么？这里有AZO是偶氮化合物，很多偶氮化合物有致癌作用，所以有的产品（比如午餐袋）客人会要求AZO检测。
奶粉中激素检测相关产品
奶粉中激素检测相关产品
“奶粉疑致性早熟”事件已经给我们敲响警钟，若从食物中摄入过量激素，将会严重损害人体健康，因此食物中激素检测日益重要。
GB/T 21981-2008 动物源食品中激素多残留检测方法，用液相色谱- 质谱/ 质谱法，对猪肉、猪肝、鸡蛋、牛奶、牛肉、鸡肉和虾等动物源食品中50种激素残留进行检测，确保食物安全。
百灵威作为中国分析行业的专业引领者，与权威机构密切共同开发国家标准中指定标准品（对照品）。
在三聚氰胺、RoHs、苏丹红等检测项目中，百灵威提供的标准品被认定为“指定产品”。
为支持《GB/T 21981-2008 动物源食品中激素多残留检测方法》及《农业部1031号公告-1-2008 动物源性食品中11种激素残留检测液相色谱－串联质谱法》需求，百灵威现为专业分析研究者提供该国标涉及的各项标准品、配套产品。
★标准品
★配套产品
更多配套分析试剂欢迎致电百灵威垂询！。
azo phth测试标准
azo phth测试标准
AZO 测试标准通常用于检测产品中是否含有AZO染料，以确保产品的安全性。
以下是一些常用的AZO测试标准：
1. 欧洲标准EN 14362-1和EN 14362-2：这些标准规定了偶氮染料中致敏
物质的检测方法，以确保产品不含有致敏物质。
2. 美国标准ASTM D6729-06：此标准也规定了偶氮染料中致敏物质的检测
方法，以确保产品的安全性。
在选择和使用测试方法时，建议先了解各种标准和方法的优缺点，并考虑到所检测产品的特性、用途以及所需结果精度等因素。
同时，要注意遵循标准的最新版本和相关的法律法规，以确保测试的准确性和合法性。
ITT Goulds Pumps 1GD Submersible Grinder Pump Dual
Goulds Pumps1GDSubmersible Grinder PumpDual Seal with OptionalSeal Sensor ProbeGoulds Pumps is a brand of ITT Residential and Commercial FEATURES■ Single phase pumps now have built-in overload protection. See control panel note on page 3.■ Impeller: Silicon bronze, multi-vane semi-open, with pump-out vanes for mechanical seal protection. Balanced for smooth operation.■ Grinder Cutter System: The anti-roping design, hardened cutter is keyed to the motor shaft for positive drive. The cutter ring is specially designed to be reversed when the first side wears out thus dou-bling its life and reducing maintenance costs. The cutter system is designed and tested to pass items found in normal wastewater.■ Casing: Heavy duty cast iron, volute type for maximum efficiency. Use with A10-12 guide rail system for ease of installation and maintenance.■ Dual Mechanical Seals: Silicon carbide vs. silicon carbide outer seal and ceramic vs. carbon inner seal, stainless steel metal parts, BUNA-N elastomers. Up-per and lower shaft seals are positioned independently and are separated by an oil-filled chamber. Optional Silicon/Tung-sten Carbide outer seal available.■ Optional Seal Sensor Probe: Located in oil-filled chamber. If pumpage should be-gin to leak past lower seal it indicates to pump control panel a fault has occurred. Requires optional Seal Fail Circuit in the control panel.■ Fasteners and Pipe Plugs: 300 series stainless steel.AGENCY LISTINGSTested to UL 778 and CSA 22.2 108 StandardsBy Canadian Standards AssociationFile #LR38549Tested to UL 778 and CSA 22.2 108 Standards By Canadian Standards Association File #LR38549Goulds Pumps is ISO 9001 Registered.1st, 2nd and 3rd Characters – Discharge Size and Type 1GD = 1¼" discharge, grinder, dual seal 4th Character – Mechanical Seals5 = silicon carbide/silicon carbide/BUNA – lower sealand carbon/ceramic/BUNA – upper seal (standard)3 = silicon carbide/tungsten carbide/BUNA – lower sealand carbon/ceramic/BUNA – upper seal (optional)5th Character – Cycle/RPM 1 = 60 Hz/3500 RPM 5 = 50 Hz/2900 RPM 6th Character – Horsepower G = 2 HP7th Character – Phase/Voltage 1 = single phase, 230 V 5 = three phase, 575 V 2 = three phase, 200 V 6 = three phase, 380 V 3 = three phase, 230 V 8 = single phase, 208 V 4 = three phase, 460 VNOMENCLATURE DESCRIPTION8th Character – Impeller Diameter A = 55⁄8", Standard C = 4¾"B = 5¼" D = 4¼"9th Character – Cord Length (Power and Sensor)A = 20' (standard) F = 50' J = 100'D = 30' G = 75'10th Character – OptionsS = Seal fail, moisture sensing circuit 1E = Epoxy paintLast Character – OptionH = Pilot duty thermal sensors 11These options add a 2-wire or 4-wire sensor cord to the pump and require optional control panel circuits to operate. See panel options on control panel bulletin BCP5.APPLICATIONSDesigned for high head sewage applications where a gravity system is not practical. Ideal for pressure sew-age systems.SPECIFICATIONS Pump:• Solids handling capabilities: 3" maximum.• Discharge: 11⁄4" NPT removable flange. • Capacities: up to 46 GPM.• Total heads: up to 106 feet TDH.Motor:• 2 HP , 3450 RPM, 60 Hz • Class "F" insulation• Rated for continuous duty fully submerged• Max. Fluid Temperature: 104º F continuous duty, 140° F intermittent duty Single Phase:• 208 or 230 volt• Built-in, auto reset, on-winding motor overload Three Phase:• 200, 230, 460 or 575 volt• Class 10 ambient compensated, overload protection required in control panel.MOTORS■ Fully submerged in oil-filled chamber. High grade turbine oil surrounds motor for more efficient heat dissipation, permanent lubrication of bearings and mechanical seal for complete protection against outside environment.■ Class F insulation.•Single phase: 2 HP , 208 or 230 volt, 60 Hertz, 3450RPM, 14/4 power cord. Motor has built-in overload with automatic reset. Start capacitor, run capacitor and starting relay are required and will be located in the control panel. See “Recommended Control Panels” in chart on this bulletin.•Three phase: 2 HP , 200, 230, 460 or 575 V , 60 Hz, 3450 RPM. 14/4 STOW. Overload protection must be provided in starter unit.■ Designed for Continuous Operation: Pump ratings are within the motor manufacturer’s recommended working limits and can be operated continuously without damage when fully submerged.■ Bearings: Upper and lower heavy duty ball bearing construction for precision positioning of parts and to carry thrust loads.■ Power (Sensor) Cables: Severe duty rated, oil and water resistant. Epoxy seal on motor end provides secondary moisture barrier in case of outer jacket damage and to prevent oil wicking. 20 foot standard with optional lengths available.■ O-ring: Assures positive sealing against contaminants and oil leakage.■ Shaft: 300 series stainless steel, keyed design, short overhang for minimum shaft deflection.■ Pump is capable of running dry without damage to mechanical components.MODEL AND MOTOR INFORMATIONLOCKED FULL LOAD ORDER NO. HP PHASE VOLTS RPM MAXIMUM ROTOR KVA EFFICIENCY RESISTANCEPOWER WEIGHT AMPS AMPS CODE % START LINE-LINE CORD LBS.1GD51G1AA 1 230 15.5120.0 P 79.0 1.37 0.62 1101GD51G8AA 208 17.5 14/41GD51G2AA 2 200 3450 14.0 44.8 J 81.0 1.8STOW 1GD51G3AA 3230 12.0 37.4 D 81.4 NA 2.8 20' 105 1GD51G4AA 460 6.0 18.7 11.1 LONG 1GD51G5AA 575 4.8 14.0 J 83.2 18.0 FEATURES (continued)Effective with December 2005 (M05) Date Codes -Single-Phase 1GD Pumps Contain a Built-in, Auto Reset Overload.Important Control Panel Requirements and Notes:1) See panel bulletin BCP5 for other available options.2) These pumps require a magnetic contactor, start and run capacitors and a starting relay in the control panel.3) CP-1GDB Capacitor packs with starting relays are available on product bulletin BCPCAP . They are for certified panel shops to “build” into a custom panel. Field installing capacitor packs into a S10020 or D10020 will negate the UL listing on that panel and is therefore not permissible.Pump Pump Seal Voltage Recommended Control Panel Order No. Fail Circuit / Phase Simplex Duplex1GD51G1A _ NO 230 / 1 S1GD2 D1GD2 1GD51G8A _ NO 208 / 1 S1GD2 D1GD2 1GD51G1A _S YES 230 / 1 S1GD2H D1GD2J 1GD51G8A _SYES208 / 1S1GD2HD1GD2J58ItemPart Name MaterialNo. 1 Impeller, multi-vane 1179 2 Castings 1003 3 Shaft–keyed 300 Series SS 4 Fasteners 300 Series SS 5 Ball bearings Steel 6 Power cable STOW, 20 feet 7 O-ring BUNA-N Outer Mech. No. Service Rotary Stationary ElastomersMetalSeal Parts OPT 10K22 Heavy duty Silicon Tungsten BUNA-N300 SeriesCarbide Carbide SS STD 10K28 Mild Silicon carbide BUNA-N300 Seriesabrasives SS Material Code Engineering Standard 1003 Cast iron — ASTM A48 Class 30 1179 Silicon bronze — ASTM C87600MATERIALS OF CONSTRUCTION8Goulds Pumps and the ITT Engineered Blocks Symbol are registered trademarks and tradenames of ITT Corporation.SPECIFICATIONS ARE SUBJECT TO CHANGE WITHOUT NOTICE.B1GD August, 2006© 2006 ITT CorporationMaximum Solid SizeN/A Minimum Casing Thickness 5⁄16"Casing Corrosion Allowance 1⁄8"Maximum Working Pressure 50 PSI Maximum Submergence50 feetMinimum SubmergenceFully submerged for continuous operation6" below top of motor for intermittent operation Maximum Environmental 40ºC (104ºF) continuous operation Temperature60ºC (140ºF) intermittent operationAPPLICATION DATACONSTRUCTION DETAILSSTANDARD PARTSBall Bearing – Upper Single row ball – SKF TM 6203-2Z Ball Bearing – Lower Single row ball – SKF TM 6206-2Z Mechanical Seals – Carbon/Ceramic – UpperStandardSilicon Carbide/Silicon Carbide – Lower Mechanical Seals – Optional Silicon Carbide/Tungsten Carbide – Lower O-Ring – Stuffing Box BUNA-N, AS 568A-256O-Ring – Motor CoverBUNA-N, AS 568A-166DIMENSIONS(All dimensions are in inches. Do not use for constructionpurposes.)Standard Optional Pump Legs Foot Order No. 4K639(Set of 3)KICKBACK。
偶氮染料的测试标准
欧洲议会和理事会指令2002/61/EC文章发布时间：2004-07-20欧洲议会和理事会指令2002/61/EC2002年7月19日对欧盟委员会关于限制某些危险物质和制剂（偶氮染料）的销售和使用的76／769／EEC号指令的第19次修改浙江省标准化研究院浙江省WTO/TBT通报咨询中心乐波娜翻译欧洲议会和欧盟理事会，关于建立欧洲共同体的条约及其第95条，关于欧委会的建议（1），关于经济和社会委员会的意见（2），遵照条约第251条规定的程序（3），鉴于：（1）国际市场工作应逐步改善生活质量，健康保障和消费者安全。
本指令提供的措施保证了较高健康标准，对消费者有保护作用。
（2）含有一定偶氮染料的纺织品和皮革制品会释放出一定的致癌芳香胺。
（3）各成员国采用或计划对使用含偶氮染料纺织品和皮革制品的限制关系到国内市场的完善和运作。
因此有必要参考成员国相关法律，修订理事会1976年7月27日关于限制销售和使用一定危险物质和制剂的法律、法规和行政命令（4）的第76/769/EEC号指令。
（4）经欧委会咨询，毒性、生态毒性和环境科学委员会(CSTEE)证实，含有偶氮染料的纺织品和皮革制品存在致癌危险。
（5）为保护人体健康，应禁止使用偶氮染料，不得将含类似染料的制品投放市场。
（6）例外情况：在2005年1月1日以前，再生纤维制成的纺织品中残余染料释放的有害芳族胺（见76/769/EEC附表第43点）含量只要低于70ppm，就仍然可以在欧盟市场上销售。
这将顾及纺织品的回收利用，对保护环境起肯定作用。
（7）关于对芳族胺的测定，欧盟有必要形成统一的检测方法。
欧委会应根据第76/769/EEC号指令第2（a）条应建立起这些方法。
检测方法很有可能由欧洲标准化委员会（CEN）起草。